Egfr - epidermal growth factor receptor Gene
Also Known as Wa5; wa2; Erbb; Errp; wa-2; Errb1; 9030024J15Rik
生物種: Mus musculus
About Egfr
This gene has 5 transcripts (splice variants), 283 orthologues, 53 paralogues and is associated with 180 phenotypes. Broad expression in liver adult (RPKM 26.7), liver E18 (RPKM 8.7) and 15 other tissues.
Summary
Enables epidermal growth factor binding activity and epidermal growth factor-activated receptor activity. Involved in cellular response to amino acid stimulus and positive regulation of fibroblast proliferation. Acts upstream of or within several processes, including animal organ development; epidermal growth factor receptor signaling pathway; and protein autophosphorylation. Located in several cellular components, including basolateral plasma membrane; endocytic vesicle; and perinuclear region of cytoplasm. Is expressed in several structures, including alimentary system; brain; integumental system; limb; and respiratory system. Used to study Coronavirus infectious disease and aortic valve disease. Human ortholog(s) of this gene implicated in several diseases, including colorectal cancer; lung non-small cell carcinoma (multiple); pancreatic cancer; prostate cancer; and pulmonary Tuberculosis. Orthologous to human EGFR (epidermal growth factor receptor). [provided by Alliance of Genome Resources, Apr 2022]
Egfr Products (2)
| mRNA | Protein | Name |
|---|---|---|
| NM_207655.2 | NP_997538.1 | epidermal growth factor receptor isoform 1 precursor |
| NM_007912.4 | NP_031938.1 | epidermal growth factor receptor isoform 2 precursor |
Gene Ontology
- Molecular Function
- Biological Process
- Cellular Component
| Cellular Component GO Annotation | Evidence | 参考文献 | 由来 |
|---|---|---|---|
| located in basolateral plasma membrane |
IDA
IDA: Inferred from direct assay
|
7723235 | MGI |
| located in cell surface |
IDA
IDA: Inferred from direct assay
|
23918928 | MGI |
| located in endocytic vesicle |
IDA
IDA: Inferred from direct assay
|
10534613 | MGI |
| located in intracellular anatomical structure |
IDA
IDA: Inferred from direct assay
|
10534613 | MGI |
| located in nucleus |
IDA
IDA: Inferred from direct assay
|
20208556 | MGI |
| located in perinuclear region of cytoplasm |
IDA
IDA: Inferred from direct assay
|
20208556 | MGI |
| is active in plasma membrane |
IDA
IDA: Inferred from direct assay
|
6248866 | MGI |
| located in plasma membrane |
IDA
IDA: Inferred from direct assay
|
7641815 | MGI |
| is active in plasma membrane |
IGI
IGI: Inferred from genetic interaction
|
28783046 | MGI |
Egfr Protein Structure
Recep_L_domain: pfam01030 (56 - 167)
Furin-like: pfam00757 (183 - 334)
Recep_L_domain: pfam01030 (361 - 480)
GF_recep_IV: pfam14843 (504 - 635)
TM_ErbB1: cd12093 (633 - 678)
PTKc_EGFR: cd05108 (705 - 1017)
- 0
- 200
- 400
- 600
- 800
- 1000
- 1210 a.a.
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
epidermal growth factor receptor |
|
Recombinant Egfr Proteins
| 製品番号 | 製品名 | アクセッション番号 | 純度 |
|---|---|---|---|
| HY-P72988 | EGFR Protein, Mouse (HEK293, Fc) | Q01279 (L25-S647) | ≥ 95%, as determined by reducing SDS-PAGE. |
| HY-P72989 | EGFR Protein, Mouse (HEK293, His, solution) | Q01279 (L25-S647) | ≥ 95%, as determined by reducing SDS-PAGE. |
Related Agents
- Approval
- Clinical Phase
- Pre-clinical Phase
Approval
| 製品番号 | 製品名 |
製品効果
|
純度 |
Rare Diseases
|
|---|---|---|---|---|
| HY-15772 | Osimertinib | Inhibitor | 99.96% | Yes |
| HY-P9907 | Trastuzumab | Inhibitor | 99.80% | Unkown |
| HY-P9905 | Cetuximab | Inhibitor | 99.81% | Unkown |
| HY-50895 | Gefitinib | Inhibitor | 99.99% | Yes |
| HY-138298A | Trastuzumab deruxtecan | Inhibitor | 99.89% | Unkown |
| HY-50896 | Erlotinib | Inhibitor | 99.99% | Yes |
| HY-10261 | Afatinib | Inhibitor | 99.92% | Yes |
| HY-138298 | Trastuzumab deruxtecan (solution) | Inhibitor | 99.40% | Unkown |
| HY-50898 | Lapatinib | Inhibitor | 99.83% | Yes |
| HY-16069 | Tucatinib | Inhibitor | 99.82% | Yes |
| HY-P9921 | Trastuzumab emtansine | Inhibitor | 99.74% | Unkown |
| HY-32721 | Neratinib | Inhibitor | 99.94% | Yes |
| HY-P9985 | Disitamab vedotin | Inhibitor | 99.06% | Unkown |
| HY-13272 | Dacomitinib | Inhibitor | 99.74% | Yes |
| HY-15772A | Osimertinib mesylate | Inhibitor | 99.97% | Yes |
| HY-109061 | Lazertinib | Inhibitor | 99.87% | Unkown |
| HY-P9921A | Trastuzumab emtansine (solution) | 98.27% | Unkown | |
| HY-12008 | Erlotinib Hydrochloride | Inhibitor | 99.94% | Yes |
| HY-10261A | Afatinib dimaleate | Inhibitor | 99.74% | Yes |
| HY-112870 | Firmonertinib | Inhibitor | 99.89% | Unkown |
| HY-112823 | Almonertinib | Inhibitor | 99.83% | Unkown |
| HY-50895A | Gefitinib hydrochloride | Inhibitor | 99.85% | Yes |
| HY-104065 | Pyrotinib | Inhibitor | 99.89% | Unkown |
| HY-132842 | Sunvozertinib | Inhibitor | 99.62% | Unkown |
| HY-N0281 | Daphnetin | Inhibitor | 99.77% | Unkown |
| HY-135815 | Mobocertinib | Inhibitor | 99.60% | Yes |
| HY-15164A | Icotinib | Inhibitor | 99.96% | Yes |
| HY-79077 | Osimertinib dimesylate | Inhibitor | 99.96% | Yes |
| HY-32721B | Neratinib maleate | Inhibitor | 99.74% | Yes |
| HY-164718 | Sevabertinib | Inhibitor | 99.90% | Unkown |
| HY-50898A | Lapatinib ditosylate | Inhibitor | 99.96% | Yes |
| HY-19730 | Olmutinib | Inhibitor | 99.88% | Unkown |
| HY-112870A | Firmonertinib mesylate | Inhibitor | 99.97% | Unkown |
| HY-15772R | Osimertinib (Standard) | Inhibitor | 99.69% | Unkown |
| HY-50898B | Lapatinib ditosylate monohydrate | Inhibitor | 99.99% | Yes |
| HY-104065B | Pyrotinib dimaleate | Inhibitor | 98.04% | Unkown |
| HY-112823B | Almonertinib hydrochloride | Inhibitor | 98.92% | Unkown |
| HY-112823A | Almonertinib mesylate | Inhibitor | 99.67% | Unkown |
| HY-135815A | Mobocertinib succinate | Inhibitor | 99.83% | Yes |
| HY-50896R | Erlotinib (Standard) | Inhibitor | 99.97% | Unkown |
| HY-16069A | Tucatinib hemiethanolate | Inhibitor | 98.82% | Yes |
| HY-15164 | Icotinib Hydrochloride | Inhibitor | 99.89% | Yes |
| HY-50895R | Gefitinib (Standard) | Inhibitor | 99.94% | Unkown |
| HY-118263 | Dacomitinib hydrate | Inhibitor | 99.54% | Unkown |
| HY-12008R | Erlotinib Hydrochloride (Standard) | Inhibitor | 99.73% | Unkown |
| HY-50898C | Lapatinib tosylate | Inhibitor | / | Unkown |
| HY-135815B | Mobocertinib mesylate | Inhibitor | / | Unkown |
| HY-10261D | Afatinib oxalate | Inhibitor | / | Unkown |
| HY-50895B | Gefitinib dihydrochloride | Inhibitor | / | Unkown |
| HY-101820A | Simotinib hydrochloride | Inhibitor | / | Unkown |
| HY-12008A | Erlotinib mesylate | Inhibitor | / | Unkown |
| 製品番号 | 製品名 |
製品効果
|
純度 |
Rare Diseases
|
|---|---|---|---|---|
| HY-P9977 | Amivantamab | Inhibitor | 99.90% | Unkown |
| HY-P9912 | Pertuzumab | Inhibitor | 99.80% | Unkown |
| HY-P99041 | Panitumumab | Inhibitor | 99.77% | Unkown |
| HY-P99380 | Zanidatamab | Inhibitor | 98.56% | Unkown |
| HY-P99507 | Zenocutuzumab | Inhibitor | 99.9% | Unkown |
| HY-P9968 | Nimotuzumab | Inhibitor | 96.80% | Unkown |
| HY-P9964 | Necitumumab | Inhibitor | 99.82% | Unkown |
| HY-P99030 | Margetuximab | Inhibitor | ≥99.0% | Unkown |
Clinical Phase
| 製品番号 | 製品名 |
製品効果
|
純度 |
Phase |
|---|---|---|---|---|
| HY-14596 | Genistein | Inhibitor | 99.82% | Phase 4 |
| HY-137433 | Befotertinib | Inhibitor | 99.77% | Phase 4 |
| HY-131686 | Ganglioside GT1b (bovine) ammonium | Activator | 98.0% | Phase 4 |
| HY-50895G | Gefitinib (GMP) | Inhibitor | / | Phase 4 |
| HY-P99813 | Patritumab deruxtecan | 99.08% | Phase 3 | |
| HY-164702 | BL-B01D1 | Inhibitor | 98.40% | Phase 3 |
| HY-18750 | Zorifertinib | Inhibitor | 99.37% | Phase 3 |
| HY-171265 | Becotatug vedotin | Degrader | 96.99% | Phase 3 |
| HY-15729 | Rociletinib | Inhibitor | 99.67% | Phase 3 |
| HY-15730 | Poziotinib | Inhibitor | 99.96% | Phase 3 |
| HY-132259 | Depatuxizumab mafodotin | 99.65% | Phase 3 | |
| HY-12872 | Nazartinib | Inhibitor | 99.53% | Phase 3 |
| HY-164762 | Trastuzumab rezetecan | Inhibitor | 98.01% | Phase 3 |
| HY-112299 | Zipalertinib | Inhibitor | 99.62% | Phase 3 |
| HY-139920 | Oritinib | Inhibitor | 99.59% | Phase 3 |
| HY-19803 | Naquotinib mesylate | Inhibitor | 98.06% | Phase 3 |
| HY-19816A | Avitinib maleate | Inhibitor | 99.86% | Phase 3 |
| HY-13314 | Tesevatinib | Inhibitor | 99.41% | Phase 3 |
| HY-120590 | Ruserontinib | Inhibitor | 99.32% | Phase 3 |
| HY-P990697 | Anvatabart | Inhibitor | 98.15% | Phase 3 |
| HY-138751A | limertinib diTFA | Inhibitor | 98.96% | Phase 3 |
| HY-118998 | TX2-121-1 | Degrader | / | Phase 3 |
| HY-10530A | Varlitinib tosylate | Inhibitor | / | Phase 3 |
| HY-109189A | Rezivertinib hydrochloride | Inhibitor | / | Phase 3 |
| HY-106204 | Nelipepimut-S | / | Phase 3 | |
| HY-N14349 | Asterriquinone | Inhibitor | / | Phase 3 |
| HY-172820 | Trastuzumab envedotin | Inhibitor | / | Phase 3 |
| HY-13050 | Sapitinib | Inhibitor | 99.93% | Phase 2 |
| HY-10367 | Canertinib | Inhibitor | 99.74% | Phase 2 |
| HY-32718 | Pelitinib | Inhibitor | 99.13% | Phase 2 |
| HY-153268 | Silevertinib | Inhibitor | 99.74% | Phase 2 |
| HY-10045 | AEE788 | Inhibitor | 98.39% | Phase 2 |
| HY-14674 | CP-724714 | Inhibitor | 98.72% | Phase 2 |
| HY-10333 | BMS-690514 | Inhibitor | 99.68% | Phase 2 |
| HY-19985 | PF-06459988 | Inhibitor | 99.10% | Phase 2 |
| HY-12972 | Mavelertinib | Inhibitor | 99.34% | Phase 2 |
| HY-17632 | Tarloxotinib bromide | Inhibitor | 98.75% | Phase 2 |
| HY-172429A | Enozertinib hemihydrate | Inhibitor | 99.98% | Phase 2 |
| HY-19815 | Olafertinib | Inhibitor | 99.51% | Phase 2 |
| HY-10251 | BMS-599626 | Inhibitor | 98.56% | Phase 2 |
| HY-107367A | Epertinib hydrochloride | Inhibitor | 98.15% | Phase 2 |
| HY-155537 | Pruvonertinib | Inhibitor | 99.50% | Phase 2 |
| HY-19909 | NRC-2694 | Antagonist | 99.84% | Phase 2 |
| HY-W423595 | BEBT-109 | Inhibitor | 98.72% | Phase 2 |
| HY-153974 | BBT-176 | Inhibitor | 98.98% | Phase 2 |
| HY-107367 | Epertinib | Inhibitor | ≥98.0% | Phase 2 |
| HY-P991092 | IBI-334 | Inhibitor | 98.18% | Phase 2 |
| HY-177414 | BB-1701 | Inhibitor | 98.81% | Phase 2 |
| HY-101756 | SDZ281-977 | 98.00% | Phase 2 | |
| HY-164387A | Sutetinib maleate | Inhibitor | / | Phase 2 |
| HY-10223 | CUDC-101 | Inhibitor | 99.05% | Phase 1 |
| HY-13501 | Mubritinib | Inhibitor | 99.91% | Phase 1 |
| HY-164202 | ORM-5029 | Inhibitor | 96.53% | Phase 1 |
| HY-18957 | Lifirafenib | Inhibitor | 98.01% | Phase 1 |
| HY-144680 | BLU-945 | Inhibitor | 99.61% | Phase 1 |
| HY-14346 | PD153035 | Inhibitor | 98.56% | Phase 1 |
| HY-171124 | Tilatamig samrotecan | Inhibitor | 95.26% | Phase 1 |
| HY-136789 | Tuxobertinib | Inhibitor | 99.88% | Phase 1 |
| HY-15196 | TAK-285 | Inhibitor | 98.99% | Phase 1 |
| HY-103443 | HKI-357 | Inhibitor | 99.24% | Phase 1 |
| HY-B0794 | AZ7550 | Inhibitor | 97.09% | Phase 1 |
| HY-116437 | Selatinib | Inhibitor | 98.56% | Phase 1 |
| HY-155079 | DZD1516 | Inhibitor | 99.62% | Phase 1 |
| HY-101820 | Simotinib | Inhibitor | 99.39% | Phase 1 |
| HY-10346 | AV-412 | Inhibitor | 99.17% | Phase 1 |
| HY-153110 | Larotinib | Inhibitor | 99.50% | Phase 1 |
| HY-139300 | Epitinib | Inhibitor | 99.95% | Phase 1 |
| HY-164694 | Emupertinib | Inhibitor | 99.10% | Phase 1 |
| HY-171747 | AMT-562 | Antagonist | 98.65% | Phase 1 |
| HY-177895 | IAM1363 | Inhibitor | 99.40% | Phase 1 |
| HY-111553 | TAS0728 | Inhibitor | 99.71% | Phase 1 |
| HY-128778 | Gozanertinib | Inhibitor | 98.37% | Phase 1 |
| HY-164307 | Pebezertinib | Inhibitor | 99.56% | Phase 1 |
| HY-15732 | BGB-102 | Inhibitor | 99.52% | Phase 1 |
| HY-164464 | BPI-15086 | Inhibitor | / | Phase 1 |
| HY-104066A | Theliatinib tartrate | / | Phase 1 | |
| HY-181954 | ZW-49 | Inhibitor | / | Phase 1 |
| HY-110039 | BIBX 1382 dihydrochloride | Inhibitor | / | Phase 1 |
| HY-153856 | TAS2940 | Inhibitor | / | Phase 1 |
| HY-110333 | BMS-599626 dihydrochloride | Inhibitor | / | Phase 1 |
| HY-177710 | MEDI4276 | / | Phase 1 |
| 製品番号 | 製品名 |
製品効果
|
純度 |
Phase |
|---|---|---|---|---|
| HY-P99041A | Panitumumab (anti-EGFR) | Inhibitor | 99.02% | Phase 4 |
| HY-P99969 | Inetetamab | Inhibitor | 96.54% | Phase 4 |
| HY-P99854A | Disitamab (powder) | Inhibitor | 98.44% | Phase 4 |
| HY-P99041B | Panitumumab (powder) | Inhibitor | / | Phase 4 |
| HY-P99275 | Patritumab | Inhibitor | 99.28% | Phase 3 |
| HY-P99406 | Petosemtamab | Degrader | 99.90% | Phase 3 |
| HY-P99676 | Izalontamab | Inhibitor | 99.89% | Phase 3 |
| HY-P99849 | Depatuxizumab | Inhibitor | 99.58% | Phase 3 |
| HY-P99155 | Zalutumumab | 98.34% | Phase 3 | |
| HY-P990049 | Becotatug | Inhibitor | 99.00% | Phase 3 |
| HY-P99437 | Anbenitamab | Inhibitor | 99.22% | Phase 3 |
| HY-P99455 | Bafisontamab | Inhibitor | 99.9% | Phase 3 |
| HY-P99831 | Coprelotamab | / | Phase 3 | |
| HY-P99630 | Gancotamab antibody | Inhibitor | ≥99.0% | Phase 3 |
| HY-P991588 | HLX-22 | Antagonist | 99.47% | Phase 3 |
| HY-P991508 | Sym004 | Inhibitor | 98.97% | Phase 3 |
| HY-P99155A | Zalutumumab (powder) | Inhibitor | / | Phase 3 |
| HY-P99268 | Seribantumab | Inhibitor | 96.043% | Phase 2 |
| HY-P9969 | Matuzumab | 99.50% | Phase 2 | |
| HY-P99936 | Elgemtumab | Inhibitor | 99.00% | Phase 2 |
| HY-P99778 | Ontuxizumab | 99.85% | Phase 2 | |
| HY-P990314 | AFM24 | Inhibitor | 96.26% | Phase 2 |
| HY-P99295 | Imgatuzumab | Inhibitor | 99.41% | Phase 2 |
| HY-P990071 | Fepixnebart | Inhibitor | 96.46% | Phase 2 |
| HY-P99605 | Cinrebafusp alfa | Inhibitor | 98.53% | Phase 2 |
| HY-P99306 | Modotuximab | Inhibitor | 99.08% | Phase 2 |
| HY-P99628 | Futuximab | Inhibitor | 98.09% | Phase 2 |
| HY-P991237 | Nezutatug | Inhibitor | 99.9% | Phase 2 |
| HY-P991571 | GC1118 | 99.22% | Phase 2 | |
| HY-P990913 | Dalmitamig | 97.158% | Phase 2 | |
| HY-P99672 | Istiratumab | Inhibitor | 98.45% | Phase 2 |
| HY-P991238 | MEDI4276 Antibody | Inhibitor | 96.5212% | Phase 2 |
| HY-P9994 | Pertuzumab zuvotolimod | Inhibitor | 98.64% | Phase 2 |
| HY-P991240 | CDX-3379 | Inhibitor | 99.38% | Phase 2 |
| HY-P991507 | SCT200 | Inhibitor | 99.09% | Phase 2 |
| HY-P991572 | MM-151 | Antagonist | / | Phase 2 |
| HY-P99500 | Cetuximab sarotalocan | Inhibitor | / | Phase 2 |
| HY-P991233 | BAT1006 | Inhibitor | / | Phase 2 |
| HY-P991524 | MM-111 | Inhibitor | / | Phase 2 |
| HY-P99896 | Runimotamab | 99.00% | Phase 1 | |
| HY-P99386 | Vesencumab | Inhibitor | 99.34% | Phase 1 |
| HY-P99304 | Lumretuzumab | Inhibitor | ≥99.0% | Phase 1 |
| HY-P99685 | Laprituximab emtansine | Inhibitor | 97.66% | Phase 1 |
| HY-P991235 | FS102 | Degrader | / | Phase 1 |
| HY-P990609 | KHK-2866 | 98.23% | Phase 1 | |
| HY-P991984 | SIBP-03 | Inhibitor | / | Phase 1 |
| HY-P991244 | REGN-1400 | Inhibitor | / | Phase 1 |
Pre-clinical Phase
| 製品番号 | 製品名 |
製品効果
|
純度 |
Rare Diseases
|
|---|---|---|---|---|
| HY-12000 | AG490 | Inhibitor | 99.86% | Unkown |
| HY-P0221 | PACAP (1-38), human, ovine, rat | Inducer | 99.99% | Unkown |
| HY-13524 | AG-1478 | Inhibitor | 99.57% | Unkown |
| HY-P10408 | Candidalysin | Activator | 99.81% | Unkown |
| HY-101084 | NSC 228155 | Activator | 99.58% | Unkown |
| HY-164992 | Trastuzumab vedotin | Inhibitor | 98.05% | Unkown |
| HY-13595 | Chrysophanol | Inhibitor | 99.73% | Unkown |
| HY-N0280 | Corosolic acid | 99.95% | Unkown | |
| HY-16558 | Butein | Inhibitor | 99.64% | Unkown |
| HY-N2409 | Delphinidin chloride | Inhibitor | 98.0% | Unkown |
| HY-171135 | Cetuximab MMAE | Inhibitor | 99.64% | Unkown |
| HY-100848 | TX1-85-1 | Inhibitor | 99.65% | Unkown |
| HY-12461 | WS6 | Activator | 99.30% | Unkown |
| HY-100958 | 4-DAMP | Inhibitor | 99.96% | Unkown |
| HY-B0793 | AZ-5104 | Inhibitor | 99.91% | Unkown |
| HY-156698 | HJM-561 | Degrader | 99.52% | Unkown |
| HY-N7922 | Urolithin M5 | 97.31% | Unkown | |
| HY-100742 | GNE-140 racemate | Inhibitor | 99.25% | Unkown |
| HY-123921 | Gefitinib-based PROTAC 3 | Degrader | 99.98% | Unkown |
| HY-19816 | Avitinib | Inhibitor | 99.95% | Unkown |
| HY-15644 | Tyrphostin 23 | Inhibitor | 98.19% | Unkown |
| HY-168438 | ERBB agonist-1 | Agonist | 99.16% | Unkown |
| HY-14596R | Genistein (Standard) | Inhibitor | 98.70% | Unkown |
| HY-108052 | Delphinidin 3-glucoside chloride | Inhibitor | 99.89% | Unkown |
| HY-N0447 | 8-Gingerol | Inhibitor | 99.82% | Unkown |
| HY-162713 | MTX-531 | Inhibitor | 99.87% | Unkown |
| HY-120852 | JG26 | Inhibitor | 98.14% | Unkown |
| HY-112411 | PD 174265 | Inhibitor | 98.35% | Unkown |
| HY-W016412 | Coenzyme Q0 | Inhibitor | 99.79% | Unkown |
| HY-129550 | BI-4020 | Inhibitor | 99.30% | Unkown |
| HY-13896 | PD168393 | Inhibitor | 98.01% | Unkown |
| HY-41404 | Piperonylic acid | 99.94% | Unkown | |
| HY-109189 | Rezivertinib | Inhibitor | 99.62% | Unkown |
| HY-100434 | PD-161570 | Inhibitor | 98.78% | Unkown |
| HY-48999A | FSK hydrochloride | 99.97% | Unkown | |
| HY-131864 | SJF-1528 | Degrader | 98.90% | Unkown |
| HY-141640 | MS154 | Inhibitor | 99.71% | Unkown |
| HY-138751 | limertinib | Inhibitor | 99.15% | Unkown |
| HY-N0211 | Cyasterone | Inhibitor | 99.58% | Unkown |
| HY-N2450 | Sulforaphene | Inhibitor | 99.78% | Unkown |
| HY-18609 | PD158780 | Inhibitor | 99.47% | Unkown |
| HY-155736 | MAPK-IN-2 | Inhibitor | 99.66% | Unkown |
| HY-W782083 | p-SCN-Bn-NOTA trihydrochloride | 99.75% | Unkown | |
| HY-125168 | EGA | Modulator | 99.76% | Unkown |
| HY-N2184 | Furanodienone | 99.90% | Unkown | |
| HY-14596S | Genistein-d4 | Inhibitor | 98.81% | Unkown |
| HY-10530 | Varlitinib | Inhibitor | 99.92% | Yes |
| HY-141676 | HyT36 | Degrader | 96.0% | Unkown |
| HY-N7005 | Clitorin | Inhibitor | 99.45% | Unkown |
| HY-15375 | Allitinib | Inhibitor | 98.88% | Unkown |
| HY-100213 | EAI045 | Inhibitor | 99.06% | Unkown |
| HY-10322 | Falnidamol | Inhibitor | 99.41% | Unkown |
| HY-N0891 | Tubeimoside II | Inhibitor | 99.90% | Unkown |
| HY-138916 | PF-06672131 | Inhibitor | 99.47% | Unkown |
| HY-10367A | Canertinib dihydrochloride | Inhibitor | 99.68% | Unkown |
| HY-157229 | STX-721 | Inhibitor | 98.25% | Unkown |
| HY-156712 | Depatuxizumab MMAE | Inhibitor | 99.73% | Unkown |
| HY-20878 | Tyrphostin AG 879 | Inhibitor | 99.26% | Unkown |
| HY-115605 | CN009543V | Agonist | 99.37% | Unkown |
| HY-N9330 | Broussoflavonol F | Inhibitor | 98.11% | Unkown |
| HY-10261B | (E/Z)-Afatinib | Inhibitor | 99.98% | Unkown |
| HY-18963 | Lavendustin A | Inhibitor | 98.95% | Unkown |
| HY-B0794B | AZ7550 Mesylate | Inhibitor | 98.70% | Unkown |
| HY-131865 | SJF-1521 | Degrader | 99.65% | Unkown |
| HY-124813 | PDZ1i | Inhibitor | 99.29% | Unkown |
| HY-161536 | PROTAC EGFR degrader 9 | Inhibitor | 98.35% | Unkown |
| HY-N2510 | Myristicin | Inhibitor | 99.89% | Unkown |
| HY-123578 | NSC689857 | Inhibitor | 99.49% | Unkown |
| HY-N2524 | Camelliaside A | Ligand | 99.65% | Unkown |
| HY-104066 | Theliatinib | Inhibitor | 99.72% | Unkown |
| HY-109061B | Lazertinib mesylate | Inhibitor | 99.85% | Unkown |
| HY-157581 | MS39 | Degrader | 99.89% | Unkown |
| HY-10325 | CL-387785 | Inhibitor | 99.31% | Unkown |
| HY-108484 | PP 3 | Inhibitor | 99.20% | Unkown |
| HY-108016 | Peruvoside | Inhibitor | 99.32% | Unkown |
| HY-134877 | BAY 2476568 | Inhibitor | 99.88% | Unkown |
| HY-12026 | WZ4002 | Inhibitor | 98.99% | Unkown |
| HY-13464 | ALK-IN-1 | Inhibitor | 99.42% | Unkown |
| HY-112097 | E260 | Inhibitor | 99.92% | Unkown |
| HY-137191 | CH7233163 | Inhibitor | 99.41% | Unkown |
| HY-147858 | PROTAC EGFR degrader 7 | Degrader | 99.48% | Unkown |
| HY-115481 | EphB1-IN-1 | Inhibitor | 99.51% | Unkown |
| HY-150611 | EGFR-IN-70 | Inhibitor | 98.12% | Unkown |
| HY-N2445 | Flavokawain C | Inhibitor | 99.79% | Unkown |
| HY-19729 | Naquotinib | Inhibitor | 98.10% | Unkown |
| HY-107364 | MTX-211 | Inhibitor | 99.81% | Unkown |
| HY-172429 | Enozertinib | Inhibitor | 98.86% | Unkown |
| HY-147219A | SIAIS164018 hydrochloride | Degrader | 98.06% | Unkown |
| HY-156640 | Rocbrutinib | Inhibitor | 99.76% | Unkown |
| HY-N4201 | β-Hydroxyisovalerylshikonin | Inhibitor | 99.83% | Unkown |
| HY-103442 | CGP52411 | Inhibitor | 99.82% | Unkown |
| HY-15772S | Osimertinib-d6 | Inhibitor | 99.70% | Unkown |
| HY-128862 | EGFR-IN-7 | Inhibitor | 99.76% | Unkown |
| HY-128576 | DS21360717 | 99.80% | Unkown | |
| HY-12013 | PD153035 Hydrochloride | Inhibitor | 99.48% | Unkown |
| HY-W018800 | 4(3H)-Quinazolinone | Inhibitor | 99.89% | Unkown |
| HY-13895 | WHI-P154 | Inhibitor | 98.77% | Unkown |
| HY-17499 | EGFR-IN-12 | Inhibitor | 99.60% | Unkown |
| HY-163094 | EGFR-IN-95 | Inhibitor | 98.76% | Unkown |
| HY-15844 | AG-825 | Inhibitor | 98.13% | Unkown |
| HY-162299 | EGFR kinase inhibitor 3 | Inhibitor | 99.03% | Unkown |
| HY-B1394 | Khellin | Inhibitor | 99.66% | Unkown |
| HY-12001 | WZ-3146 | Inhibitor | 99.28% | Unkown |
| HY-13897 | CNX-2006 | Inhibitor | 98.00% | Unkown |
| HY-161275 | BI-4732 | Inhibitor | 98.81% | Unkown |
| HY-147183B | JBJ-09-063 hydrochloride | Inhibitor | 99.37% | Unkown |
| HY-12010 | BMS-599626 Hydrochloride | Inhibitor | 98.90% | Unkown |
| HY-147941A | MS9427 TFA | Degrader | 98.38% | Unkown |
| HY-130616 | EGFR-IN-11 | Inhibitor | 98.76% | Unkown |
| HY-111415 | EGFR-IN-5 | Inhibitor | 99.49% | Unkown |
| HY-153796 | PROTAC Her3 Degrader-8 | Degrader | 99.60% | Unkown |
| HY-172470 | DSPE-PEG2000-GE11 | 95.29% | Unkown | |
| HY-144304 | PROTAC EGFR degrader 2 | Inhibitor | 95.09% | Unkown |
| HY-161408 | GePhos1 | 98.88% | Unkown | |
| HY-18603 | FIIN-3 | Inhibitor | 99.01% | Unkown |
| HY-139617 | Sec61-IN-3 | Inhibitor | 99.22% | Unkown |
| HY-13427 | Allitinib tosylate | Inhibitor | 99.54% | Unkown |
| HY-147942 | MS9449 | Degrader | 98.95% | Unkown |
| HY-136430 | JCN037 | Inhibitor | 99.09% | Unkown |
| HY-43533 | Tarlox-TKI | Inhibitor | 98.79% | Unkown |
| HY-161537 | EGFR ligand-9 | Inhibitor | 98.80% | Unkown |
| HY-N1988 | Cucurbitacin IIa | Inhibitor | 99.90% | Unkown |
| HY-153901 | PROTAC EGFR degrader 8 | Degrader | 98.90% | Unkown |
| HY-101960A | Tyrphostin A51 | Inhibitor | 99.0% | Unkown |
| HY-P4082 | ErbB-2-binding peptide-1 | Ligand | 99.52% | Unkown |
| HY-146349 | PROTAC EGFR degrader 4 | Degrader | 99.70% | Unkown |
| HY-175252 | PROTAC EGFR degrader 14 | Degrader | 99.26% | Unkown |
| HY-161633 | PROTAC EGFR degrader 11 | Degrader | 99.20% | Unkown |
| HY-110406 | 13(S)-HPODE | Activator | 95.05% | Unkown |
| HY-N1073 | Wighteone | Inhibitor | 98.71% | Unkown |
| HY-149530 | EGFR-IN-86 | Inhibitor | 99.92% | Unkown |
| HY-P5314 | OK2 | Inhibitor | 99.13% | Unkown |
| HY-117155 | PKI-166 | Inhibitor | 98.92% | Unkown |
| HY-P2503 | EGFR Protein Tyrosine Kinase Substrate | 99.46% | Unkown | |
| HY-163428 | Perzebertinib | Inhibitor | / | Unkown |
| HY-12029 | WZ8040 | Inhibitor | 98.29% | Unkown |
| HY-138627A | AST5902 trimesylate | Inhibitor | 98.75% | Unkown |
| HY-150023 | BI-1622 | Inhibitor | 98.02% | Unkown |
| HY-147183A | JBJ-09-063 TFA | Inhibitor | 99.64% | Unkown |
| HY-124674A | CCT365623 hydrochloride | Inhibitor | 98.07% | Unkown |
| HY-W013857 | Lavendustin C | Inhibitor | 98.17% | Unkown |
| HY-P10792 | HER2-targeted peptide H6F | 98.85% | Unkown | |
| HY-P1828A | EGFRvIII peptide (PEPvIII) TFA | 98.73% | Unkown | |
| HY-101219 | VEGFR-IN-1 | Inhibitor | 99.07% | Unkown |
| HY-RS04209 | EGFR Human Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-101429 | RG13022 | Inhibitor | 96.74% | Unkown |
| HY-123952 | RTC-5 | Inhibitor | 99.37% | Unkown |
| HY-19985A | (3S,4S)-PF-06459988 | 98.97% | Unkown | |
| HY-103566 | LY456236 | Inhibitor | 99.57% | Unkown |
| HY-15336 | AG 555 | Inhibitor | 98.0% | Unkown |
| HY-157579 | MS154N | 99.30% | Unkown | |
| HY-123035 | Gamendazole | Inhibitor | 99.44% | Unkown |
| HY-112293 | GW2974 | 99.16% | Unkown | |
| HY-177008 | PROTAC HER2 degrader-1 | Degrader | 98.0% | Unkown |
| HY-P11308 | Cys-GE11 | 98.03% | Unkown | |
| HY-103440 | EGFR/ErbB-2/ErbB-4 inhibitor-3 | Inhibitor | 96.78% | Unkown |
| HY-161126 | EGFR-IN-98 | Inhibitor | 99.12% | Unkown |
| HY-79511 | FAAH-IN-2 | Ligand | 99.12% | Unkown |
| HY-175839 | PROTAC EGFR degrader 15 | Degrader | 99.23% | Unkown |
| HY-101041 | (E)-AG 556 | Inhibitor | 99.91% | Unkown |
| HY-126320 | EGFR-IN-8 | Inhibitor | 98.01% | Unkown |
| HY-164919 | Calotatug ginistinag | Inhibitor | 95.94% | Unkown |
| HY-150024 | BI-4142 | Inhibitor | 98.02% | Unkown |
| HY-15769 | WHI-P180 | Inhibitor | 99.84% | Unkown |
| HY-100214 | EAI001 | Inhibitor | 99.93% | Unkown |
| HY-142283AS | Dosimertinib-d5 mesylate | Inhibitor | 99.50% | Unkown |
| HY-111138 | CZC-8004 | Inhibitor | 99.81% | Unkown |
| HY-112474 | Tyrphostin AG 112 | Inhibitor | 98.31% | Unkown |
| HY-13984 | NT-1 | Inhibitor | 99.40% | Unkown |
| HY-112420 | EGFR/ErbB-2-IN-2 | Inhibitor | 99.45% | Unkown |
| HY-131864A | SJF-1528 hemihydrate | Degrader | 98.90% | Unkown |
| HY-118532 | Tyrphostin AG30 | Inhibitor | 98.51% | Unkown |
| HY-N7424 | 4,7-Dihydroxycoumarin | Inhibitor | 98.25% | Unkown |
| HY-172920 | Wnt/β-catenin-IN-6 | Inhibitor | 98.34% | Unkown |
| HY-P10224A | G7-18NATE TFA | 98.06% | Unkown | |
| HY-157480 | EGFR/AURKB-IN-1 | Inhibitor | 99.43% | Unkown |
| HY-12806 | AG1557 | Inhibitor | 99.54% | Unkown |
| HY-142512 | EGFR-IN-24 | Inhibitor | 98.71% | Unkown |
| HY-101042 | AG-494 | Inhibitor | 98.69% | Unkown |
| HY-N6577 | Astragaloside VI | 99.95% | Unkown | |
| HY-135805B | (Rac)-JBJ-04-125-02 acetate | / | Unkown | |
| HY-15729A | Rociletinib hydrobromide | Inhibitor | 98.04% | Yes |
| HY-107459 | (E/Z)-AG490 | Inhibitor | 99.71% | Unkown |
| HY-156284 | EGFR-IN-89 | Inhibitor | 98.75% | Unkown |
| HY-N6932 | Voacamine | 99.64% | Unkown | |
| HY-101450 | PF-6274484 | Inhibitor | 98.76% | Unkown |
| HY-119944 | JND3229 | Inhibitor | 99.38% | Unkown |
| HY-153110A | Larotinib mesylate hydrate | Inhibitor | 98.66% | Unkown |
| HY-141481 | DP-C-4 | Inhibitor | 98.15% | Unkown |
| HY-156741A | EGFR-IN-87 hydrochloride | Inhibitor | 98.0% | Unkown |
| HY-179572 | STA-013 | Inhibitor | 99.18% | Unkown |
| HY-145960A | MC-Val-Cit-PAB-Amide-TLR7 agonist 4 formic | Agonist | 97.70% | Unkown |
| HY-112345 | PD-089828 | Inhibitor | 98.07% | Unkown |
| HY-164763 | SHR-A1201 | Inhibitor | 97.35% | Unkown |
| HY-101426 | RG14620 | Inhibitor | 99.02% | Unkown |
| HY-P11078A | LARLLT TFA | 99.89% | Unkown | |
| HY-149889 | EGFR-IN-78 | Inhibitor | 99.57% | Unkown |
| HY-50896S | Erlotinib-d6 | Inhibitor | 99.84% | Unkown |
| HY-131686A | Ganglioside GT1b (porcine) ammonium | Activator | 98% | Unkown |
| HY-RS04466 | ERBB2 Human Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-101006 | Methyl 2,5-dihydroxycinnamate | Inhibitor | 99.77% | Unkown |
| HY-P1855 | HER2/neu (654-662) GP2 | 98.26% | Unkown | |
| HY-139997 | DDC-01-163 | Degrader | 99.05% | Unkown |
| HY-158149 | T-1-PMPA | Inhibitor | 99.70% | Unkown |
| HY-161927 | EGFR-TK-IN-4 | Inhibitor | 99.90% | Unkown |
| HY-143337 | EGFR-IN-47 | Inhibitor | 96.01% | Unkown |
| HY-RS04472 | ERBB4 Human Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-101522 | CHMFL-EGFR-202 | Inhibitor | 99.75% | Unkown |
| HY-100064 | O-Desmethyl gefitinib | Inhibitor | 99.40% | Unkown |
| HY-161781 | HVH-2930 | Inhibitor | 96.54% | Unkown |
| HY-100923 | H-9 Dihydrochloride | Inhibitor | 98.98% | Unkown |
| HY-50898S | Lapatinib-d4 | Inhibitor | 99.02% | Unkown |
| HY-15801 | HG-14-10-04 | Inhibitor | 98.53% | Unkown |
| HY-162890 | EGFR-IN-122 | Inhibitor | 99.98% | Unkown |
| HY-151159 | DHFR-IN-4 | Inhibitor | 99.19% | Unkown |
| HY-N1166 | Tephrosin | 98.02% | Unkown | |
| HY-103441 | JNJ28871063 hydrochloride | Inhibitor | 98.36% | Unkown |
| HY-172414 | Andamertinib | Inhibitor | 99.06% | Unkown |
| HY-170820 | XYD049 | Inhibitor | 99.46% | Unkown |
| HY-133780 | Afatinib impurity 11 | Inhibitor | 99.10% | Unkown |
| HY-156872 | MTX-216 | Inhibitor | / | Unkown |
| HY-113599 | Isoprocurcumenol | Activator | 95.41% | Unkown |
| HY-157582 | MS39N | Control | 98.0% | Unkown |
| HY-50895S2 | Gefitinib-d3 | Inhibitor | 98.39% | Unkown |
| HY-13450 | ZM 449829 | Inhibitor | 99.73% | Unkown |
| HY-112870AS | Firmonertinib-d3 mesylate | 99.00% | Unkown | |
| HY-50895S | Gefitinib-d8 | Inhibitor | 98.42% | Unkown |
| HY-135805A | (Rac)-JBJ-04-125-02 | Inhibitor | / | Unkown |
| HY-19617 | EGFR-IN-1 | Inhibitor | / | Unkown |
| HY-131067 | EMI56 | Inhibitor | 99.36% | Unkown |
| HY-100962 | (E)-AG 99 | Inhibitor | 98.12% | Unkown |
| HY-19617A | EGFR-IN-1 hydrochloride | Inhibitor | / | Unkown |
| HY-152852 | Mefatinib free base | Inhibitor | 99.40% | Unkown |
| HY-132842A | (S)-Sunvozertinib | Inhibitor | 99.05% | Unkown |
| HY-138627 | AST5902 | Inhibitor | / | Unkown |
| HY-147183 | JBJ-09-063 | Inhibitor | / | Unkown |
| HY-130608 | Mutated EGFR-IN-3 | Inhibitor | / | Unkown |
| HY-147941 | MS9427 | Degrader | 95.29% | Unkown |
| HY-139300A | Epitinib succinate | Inhibitor | 99.01% | Unkown |
| HY-115716 | EGFR-IN-17 | Inhibitor | 98.18% | Unkown |
| HY-108486 | Herbimycin A | Degrader | 99% | Unkown |
| HY-P992138 | Vadalentamig | Inhibitor | 95.29% | Unkown |
| HY-101958 | Tyrphostin 25 | Inhibitor | 99.00% | Unkown |
| HY-183682 | AZ14289671 | Inhibitor | 98.99% | Unkown |
| HY-135805 | JBJ-04-125-02 | Inhibitor | / | Unkown |
| HY-147219 | SIAIS164018 | Degrader | / | Unkown |
| HY-157413 | YS-67 | Inhibitor | 99.41% | Unkown |
| HY-P992128 | Rinumafusp alfa | Inhibitor | 97.09% | Unkown |
| HY-P2673 | Lys-Arg-Thr-Leu-Arg-Arg | / | Unkown | |
| HY-170928 | DA-0157 | Inhibitor | 99.59% | Unkown |
| HY-164387 | Sutetinib | Inhibitor | 99.27% | Unkown |
| HY-101007A | (+)-Tyrphostin B44 | Inhibitor | 99.10% | Unkown |
| HY-145960 | MC-Val-Cit-PAB-Amide-TLR7 agonist 4 | Agonist | 99.39% | Unkown |
| HY-161618 | MJ04 | Inhibitor | 98.08% | Unkown |
| HY-13272S2 | Dacomitinib-d10 dihydrochloride | Inhibitor | ≥95.0% | Unkown |
| HY-N10103 | Neoschaftoside | Modulator | 98.04% | Unkown |
| HY-155005 | EGFR mutant-IN-2 | Inhibitor | 97.0% | Unkown |
| HY-12008S | Erlotinib-d6 hydrochloride | Inhibitor | 98.13% | Unkown |
| HY-100499 | Tyrphostin AG 528 | Inhibitor | 98.0% | Unkown |
| HY-144677 | pan-HER-IN-2 | Inhibitor | 98.10% | Unkown |
| HY-155358 | Os30 | Inhibitor | 98.34% | Unkown |
| HY-N6651 | Isocryptotanshinone | Inhibitor | ≥98.0% | Unkown |
| HY-162254 | EGFR/ACK1-IN-1 | Inhibitor | 98.19% | Unkown |
| HY-149636 | Multi-target kinase inhibitor 2 | Inhibitor | 99.82% | Unkown |
| HY-155285 | YS-363 | Inhibitor | 99.52% | Unkown |
| HY-P2673A | Lys-Arg-Thr-Leu-Arg-Arg acetate | / | Unkown | |
| HY-126850 | 4-Epidoxycycline | / | Unkown | |
| HY-156912 | Tyrosine kinase-IN-7 | Inhibitor | 99.25% | Unkown |
| HY-12872B | Nazartinib S-enantiomer | 95.10% | Unkown | |
| HY-B0794A | AZ7550 hydrochloride | Inhibitor | 98.66% | Unkown |
| HY-131088 | N3-PEG8-Phe-Lys-PABC-Gefitinib | Inhibitor | / | Unkown |
| HY-131088A | N3-PEG8-Phe-Lys-PABC-Gefitinib TFA | Inhibitor | / | Unkown |
| HY-147858A | PROTAC EGFR degrader 7 diTFA | Degrader | 97.15% | Unkown |
| HY-50895S1 | Gefitinib-d6 | Inhibitor | 98.2% | Unkown |
| HY-158310 | SOS1/EGFR-IN-1 | Inhibitor | 99.54% | Unkown |
| HY-153111 | EGFR/HER2-IN-9 | Inhibitor | 98.73% | Unkown |
| HY-P3744 | pp60v-src Autophosphorylation site | 99.93% | Unkown | |
| HY-15772S1 | Osimertinib-13C,d3 | 99.14% | Unkown | |
| HY-19617B | EGFR-IN-1 TFA | Inhibitor | 99.38% | Unkown |
| HY-129510 | 4-Methyl erlotinib | Inhibitor | 99.34% | Unkown |
| HY-151048 | JBJ-07-149 | Inhibitor | 99.09% | Unkown |
| HY-150610 | EGFR-IN-69 | Inhibitor | 99.58% | Unkown |
| HY-156741 | EGFR-IN-87 | Inhibitor | / | Unkown |
| HY-U00002 | ZD-4190 | Inhibitor | 98.08% | Unkown |
| HY-111452 | EGFR-IN-85 | Inhibitor | / | Unkown |
| HY-183068 | AP4-43 | Inhibitor | 99.76% | Unkown |
| HY-14347 | EBE-A22 | Control | 99.76% | Unkown |
| HY-E70715 | ERBB2 775YVMA776 Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-15772S3 | Asandeutertinib | Inhibitor | 99.75% | Unkown |
| HY-108931 | AG 1406 | Inhibitor | 99.03% | Unkown |
| HY-126319 | SU5204 | Inhibitor | 99.46% | Unkown |
| HY-138072 | EMI1 | Inhibitor | 99.45% | Unkown |
| HY-103439 | GW583340 dihydrochloride | Inhibitor | / | Unkown |
| HY-10346A | AV-412 free base | Inhibitor | 98.10% | Unkown |
| HY-10261S | Afatinib-d6 | Inhibitor | 99.0% | Unkown |
| HY-B0794S | AZ7550-d5 | Inhibitor | / | Unkown |
| HY-W109039 | EGFR ligand-15 | 97.03% | Unkown | |
| HY-P990698 | Umizortamig | 96.90% | Unkown | |
| HY-W001520 | 1-Methyl-1H-pyrrolo[2,3-b]pyridine | / | Unkown | |
| HY-164476 | ES-072 | Inhibitor | 98.05% | Unkown |
| HY-12872A | Nazartinib mesylate | Inhibitor | / | Unkown |
| HY-21291 | SU-4313 | Modulator | 99.31% | Unkown |
| HY-123766 | EGFR-IN-99 | Inhibitor | 98.09% | Unkown |
| HY-P992130 | Rolditamig | Inhibitor | 95.26% | Unkown |
| HY-185832 | SYS6010 | Inhibitor | / | Unkown |
| HY-185816 | TQB2102 | Inhibitor | / | Unkown |
| HY-18750A | Zorifertinib hydrochloride | Inhibitor | / | Unkown |
| HY-19981B | Derazantinib dihydrochloride | Inhibitor | / | Unkown |
| HY-135914 | JBJ-02-112-05 | Inhibitor | / | Unkown |
| HY-100520 | EGFR-IN-2 | Inhibitor | / | Unkown |
| HY-142283 | Dosimertinib | Inhibitor | / | Unkown |
| HY-163354 | EGFR-IN-103 | Inhibitor | / | Unkown |
| HY-B0793S1 | AZ-5104-d2 | Inhibitor | / | Unkown |
| HY-132883 | EGFR/CSC-IN-1 | Inhibitor | / | Unkown |
| HY-138298C | Trastuzumab deruxtecan (DAR4) | Inhibitor | / | Unkown |
| HY-144048 | EGFR-IN-31 | / | Unkown | |
| HY-139920A | Oritinib mesylate | Inhibitor | / | Unkown |
| HY-128860 | Mutated EGFR-IN-2 | Inhibitor | / | Unkown |
| HY-143734 | HER2-IN-6 | / | Unkown | |
| HY-168968S | ZJY-54 | Inhibitor | / | Unkown |
| HY-125841 | EGFR mutant-IN-1 | Inhibitor | / | Unkown |
| HY-112806 | ST8155AA1 | / | Unkown | |
| HY-138746 | EGFR-IN-15 | Inhibitor | 96.21% | Unkown |
| HY-123726 | ErbB-1/ErbB-2 tyrosine kinase-IN-1 | / | Unkown | |
| HY-131066 | EMI48 | Inhibitor | 99.45% | Unkown |
| HY-10407G | SU 5402 (GMP) | Inhibitor | / | Unkown |
| HY-147303 | Sacibertinib | Inhibitor | / | Unkown |
| HY-147407 | Imbotolimod | Inhibitor | / | Unkown |
| HY-152852A | Mefatinib | Inhibitor | 98.90% | Unkown |
| HY-137433A | Befotertinib mesylate | Inhibitor | / | Unkown |
| HY-115951 | EGFR/HER2-IN-2 | Inhibitor | / | Unkown |
| HY-173188 | EGFR-IN-154 | Inhibitor | / | Unkown |
| HY-152019 | EGFR/C797S-IN-1 | Inhibitor | / | Unkown |
| HY-13595R | Chrysophanol (Standard) | Inhibitor | / | Unkown |
| HY-131710 | PDE5-IN-3 | Inhibitor | / | Unkown |
| HY-E70703 | EGFR d752-759 Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-185276 | EGFR-IN-204 | Inhibitor | 98.57% | Unkown |
| HY-N3634 | Corylifol C | / | Unkown | |
| HY-161923 | EGFR-IN-120 | Inhibitor | / | Unkown |
| HY-158177 | EGFR T790M/L858R-IN-6 | Inhibitor | / | Unkown |
| HY-163453 | HER2-IN-19 | Inhibitor | / | Unkown |
| HY-181776 | c-Met-IN-31 | Inhibitor | / | Unkown |
| HY-182064 | EGFR-IN-206 | Inhibitor | / | Unkown |
| HY-170968 | EGFR-IN-150 | Inhibitor | / | Unkown |
| HY-181829 | Ctx-L3 | Degrader | / | Unkown |
| HY-19730A | Olmutinib hydrochloride | Inhibitor | / | Unkown |
| HY-163663 | AZ14133346 | Inhibitor | / | Unkown |
| HY-E70709 | EGFR T790M Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-174232 | EGFR/CA-IX-IN-1 | Inhibitor | / | Unkown |
| HY-E70711 | EGFR T790M/L858R Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-180917 | PROTAC EGFR degrader 17 | Degrader | / | Unkown |
| HY-187533 | EGFR AUTOTAC-1 | Degrader | / | Unkown |
| HY-179600 | Dyrk1A-IN-16 | Inhibitor | / | Unkown |
| HY-181657 | EGFR-IN-200 | Inhibitor | / | Unkown |
| HY-172897 | EGFR/DHFR-IN-2 | Inhibitor | / | Unkown |
| HY-158178 | EGFR T790M/L858R-IN-7 | Inhibitor | / | Unkown |
| HY-165394 | Melafolone | Inhibitor | / | Unkown |
| HY-156097 | Anticancer agent 158 | Inhibitor | / | Unkown |
| HY-152144 | EGFR-IN-75 | Inhibitor | / | Unkown |
| HY-172623 | EGFR/HER2-IN-17 | Inhibitor | / | Unkown |
| HY-P11944 | Peptide 22 | Chemical | / | Unkown |
| HY-151981 | EGFR-IN-74 | Inhibitor | / | Unkown |
| HY-E70698 | EGFR d746-750/C797S Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-180536 | HB-EGF-IN-1 | Inhibitor | / | Unkown |
| HY-152852S | Mefatinib-d6 free base | Inhibitor | / | Unkown |
| HY-10261AS | Afatinib-d6 dimaleate | Inhibitor | / | Unkown |
| HY-158988 | EGFR-IN-114 | Inhibitor | / | Unkown |
| HY-147798 | EGFR/HER2/CDK9-IN-3 | Inhibitor | / | Unkown |
| HY-183310 | EGFR-IN-210 | Inhibitor | / | Unkown |
| HY-156639 | EGFR/ErbB-2 inhibitor-1 | Inhibitor | / | Unkown |
| HY-153744 | JGK-068S | Inhibitor | / | Unkown |
| HY-155178 | Antiproliferative agent-34 | Inhibitor | / | Unkown |
| HY-168151 | EGFR-IN-128 | Inhibitor | / | Unkown |
| HY-172091 | CZY43 | Degrader | / | Unkown |
| HY-163434 | PRMT5/EGFR-IN-1 | Inhibitor | / | Unkown |
| HY-181775 | VEGFR-2/c-Met/EGFR-IN-1 | Inhibitor | / | Unkown |
| HY-P10659 | Self-assembling peptide pY1 | / | Unkown | |
| HY-147796 | EGFR/HER2/CDK9-IN-1 | Inhibitor | / | Unkown |
| HY-178057 | EGFR-IN-176 | Inhibitor | / | Unkown |
| HY-P11761 | HYNIC-H10F | Ligand | / | Unkown |
| HY-185227 | EphB4-IN-1 | Inhibitor | / | Unkown |
| HY-P5258 | Oligopeptide-41 | Inducer | 98.05% | Unkown |
| HY-162099 | VEGFR-IN-4 | Inhibitor | / | Unkown |
| HY-B0793G | AZ-5104 (GMP) | Inhibitor | / | Unkown |
| HY-179529 | EGFR/InhA-IN-1 | Inhibitor | / | Unkown |
| HY-181056 | EGFR/COX-2-IN-3 | Inhibitor | 99.76% | Unkown |
| HY-172877 | EGFR/BRAFV600E-IN-5 | Inhibitor | / | Unkown |
| HY-178942 | EGFR/VEGFR2-IN-9 | Inhibitor | / | Unkown |
| HY-187334 | EGFR-IN-216 | Inhibitor | / | Unkown |
| HY-174231 | EGFR-IN-163 | Inhibitor | / | Unkown |
| HY-144054 | EGFR-IN-37 | Inhibitor | / | Unkown |
| HY-173367 | Anticancer agent 271 | Inhibitor | / | Unkown |
| HY-183277 | EGFR-IN-209 | Inhibitor | / | Unkown |
| HY-103566A | LY456236 free base | Inhibitor | / | Unkown |
| HY-146170 | Anticancer agent 69 | Inhibitor | / | Unkown |
| HY-178448 | EGFR-IN-178 | Inhibitor | / | Unkown |
| HY-187838S | Adonertinib | Inhibitor | / | Unkown |
| HY-162891 | EGFR-IN-123 | Inhibitor | / | Unkown |
| HY-178116 | HER2-IN-23 | Inhibitor | / | Unkown |
| HY-W008914 | (E/Z)-CP-724714 | Inhibitor | / | Unkown |
| HY-P5742 | ELAAWCRWGFLLALLPPGIAG | / | Unkown | |
| HY-164056 | EGFR T790M/L858R-IN-8 | Inhibitor | 99.20% | Unkown |
| HY-150782 | UNC-CA359 | Inhibitor | / | Unkown |
| HY-171884 | BI-8128 | Inhibitor | / | Unkown |
| HY-50898S2 | Lapatinib-d5 | Inhibitor | / | Unkown |
| HY-E70704 | EGFR G719C Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-162589 | Lw13 | Inhibitor | / | Unkown |
| HY-178311 | EGFR Ligand-Linker Conjugates 4 | Ligand | / | Unkown |
| HY-144097 | HER2-IN-8 | Inhibitor | / | Unkown |
| HY-178242 | PROTAC EGFR degrader 16 | Degrader | / | Unkown |
| HY-180964 | Lys-PEG3-BA | Degrader | / | Unkown |
| HY-112405 | BPIQ-I | Inhibitor | / | Unkown |
| HY-P2548 | pp60 (v-SRC) Autophosphorylation Site, Phosphorylated | / | Unkown | |
| HY-175171 | Anticancer agent 276 | Inhibitor | / | Unkown |
| HY-101959 | Tyrphostin AG213 | Inhibitor | / | Unkown |
| HY-15772GL | Osimertinib (GMP Like) | Inhibitor | / | Unkown |
| HY-13524A | AG-1478 hydrochloride | Inhibitor | / | Unkown |
| HY-RS04211 | Egfr Rat Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-157402 | Topoisomerase II/EGFR-IN-1 | / | Unkown | |
| HY-163722 | EGFR/DHFR-IN-1 | Inhibitor | / | Unkown |
| HY-147995 | EGFR-IN-64 | Inhibitor | / | Unkown |
| HY-208666 | EGFR-IN-215 | Inhibitor | / | Unkown |
| HY-144760 | EGFR-IN-3 | Inducer | / | Unkown |
| HY-172534 | BPN-01 | Substrate | / | Unkown |
| HY-P5745A | TYVPANASL TFA | / | Unkown | |
| HY-175809 | SRT6 | Inhibitor | / | Unkown |
| HY-P11752 | Cyclo(KLARLLT) | Ligand | / | Unkown |
| HY-184719 | VEGFR-2-IN-88 | Inhibitor | / | Unkown |
| HY-168623 | EGFR-IN-134 | Inhibitor | / | Unkown |
| HY-181142 | Antitumor agent-213 | / | Unkown | |
| HY-149275 | PKM2/PDK1-IN-1 | Inhibitor | / | Unkown |
| HY-182914 | NGI-189 | Inhibitor | 99.29% | Unkown |
| HY-173038 | EGFR-IN-151 | Inhibitor | / | Unkown |
| HY-160087 | SG3376 | Ligand | / | Unkown |
| HY-147741 | DPPY | Inhibitor | / | Unkown |
| HY-163418 | HER2-IN-17 | Inhibitor | / | Unkown |
| HY-181097 | EGFR-IN-192 | Inhibitor | / | Unkown |
| HY-158153 | EGFR-IN-108 | Inhibitor | / | Unkown |
| HY-144052 | EGFR-IN-35 | Inhibitor | / | Unkown |
| HY-181714 | EGFR-IN-203 | Inhibitor | / | Unkown |
| HY-151377 | RET-IN-19 | Inhibitor | / | Unkown |
| HY-N1988R | Cucurbitacin IIa (Standard) | Inhibitor | / | Unkown |
| HY-147794 | CDK9-IN-41 | Inhibitor | 98.84% | Unkown |
| HY-181502 | EGFR-IN-197 | Inhibitor | / | Unkown |
| HY-185833 | ADC Control Human IgG1-JSSW-001 | Inhibitor | / | Unkown |
| HY-163657 | HER2-IN-20 | Inhibitor | / | Unkown |
| HY-173118 | EGFR-IN-152 | Inhibitor | / | Unkown |
| HY-158313 | PROTAC EGFR degrader 13 | Inhibitor | / | Unkown |
| HY-50898S3 | Lapatinib-d4-1 | Inhibitor | / | Unkown |
| HY-180922 | EGFR kinase-IN-8 | Inhibitor | / | Unkown |
| HY-170787 | TZEP7 | Inhibitor | / | Unkown |
| HY-172104 | EGFR-IN-143 | Inhibitor | / | Unkown |
| HY-181061 | COX/5-LO-IN-2 | Inhibitor | / | Unkown |
| HY-172795 | EGFR-IN-158 | Inhibitor | / | Unkown |
| HY-103439A | GW583340 | Inhibitor | / | Unkown |
| HY-157398 | EGFR T790M/L858R-IN-3 | Inhibitor | / | Unkown |
| HY-15268 | PP487 | Inhibitor | / | Unkown |
| HY-146228 | HSP90-IN-13 | Inhibitor | / | Unkown |
| HY-144605 | PROTAC EGFR degrader 3 | Inhibitor | 97.39% | Unkown |
| HY-176744 | HER2-IN-22 | Inhibitor | / | Unkown |
| HY-184311 | EGFR-IN-214 | Inhibitor | / | Unkown |
| HY-402309 | IGF-1R modulator 1 | Modulator | / | Unkown |
| HY-182005 | EGFR/VEGFR2-IN-12 | Inhibitor | / | Unkown |
| HY-175297 | EGFR T790M/VEGFR-2-IN-1 | Inhibitor | / | Unkown |
| HY-157399 | EGFR/HER2-IN-10 | Inhibitor | / | Unkown |
| HY-179150 | EGFR-TK-IN-6 | Inhibitor | / | Unkown |
| HY-139884 | EGFR-IN-18 | Inhibitor | / | Unkown |
| HY-172621 | EGFR-IN-159 | Inhibitor | / | Unkown |
| HY-E70708 | EGFR L861Q Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-145867 | EGFR-IN-45 | Inhibitor | / | Unkown |
| HY-P10792A | HYNIC-H6F | Ligand | / | Unkown |
| HY-168655 | EGFR/VEGFR2-IN-3 | Inhibitor | / | Unkown |
| HY-171958 | PROTAC EGFR degrader 12 | Degrader | / | Unkown |
| HY-169308 | EGFR-IN-132 | Inhibitor | / | Unkown |
| HY-158018 | EGFR-TK-IN-2 | Inhibitor | / | Unkown |
| HY-103437 | EGFR-IN-80 | Inhibitor | / | Unkown |
| HY-13314A | Tesevatinib tosylate | Inhibitor | / | Unkown |
| HY-155118 | EGFR-IN-81 | Inhibitor | / | Unkown |
| HY-157166 | EGFR kinase inhibitor 2 | Inhibitor | / | Unkown |
| HY-149633 | EGFR/HER2/DHFR-IN-3 | Inhibitor | / | Unkown |
| HY-173500 | MG-3C | Inhibitor | / | Unkown |
| HY-180966 | Gly-PEG3-BA | Degrader | / | Unkown |
| HY-182073 | EGFR-IN-207 | Inhibitor | / | Unkown |
| HY-18957B | Lifirafenib maleate | Inhibitor | / | Unkown |
| HY-164489 | KU004 | Inhibitor | / | Unkown |
| HY-157994 | EGFR WT/T790M-IN-2 | Inhibitor | / | Unkown |
| HY-147862 | EGFR-IN-62 | Inhibitor | / | Unkown |
| HY-178157 | Multi-target kinase-IN-7 | Inhibitor | / | Unkown |
| HY-168577 | KRAS G12D inhibitor 25 | Degrader | / | Unkown |
| HY-147860 | EGFR-IN-61 | Inhibitor | / | Unkown |
| HY-149556 | MTX-241F | Inhibitor | / | Unkown |
| HY-180541 | EGFR-IN-190 | Inhibitor | / | Unkown |
| HY-118900 | CP-654577 | Inhibitor | / | Unkown |
| HY-175588 | EGFR-IN-170 | Inhibitor | / | Unkown |
| HY-181659 | EGFR-IN-201 | Inhibitor | / | Unkown |
| HY-116504 | WB-308 | Inhibitor | / | Unkown |
| HY-151161 | EGFR/HER2-IN-8 | Inhibitor | / | Unkown |
| HY-175837 | EGFR-IN-172 | Inhibitor | / | Unkown |
| HY-142680 | EGFR-IN-23 | Inhibitor | / | Unkown |
| HY-149824 | EGFR T790M/L858R-IN-2 | Inhibitor | 99.66% | Unkown |
| HY-146239 | EGFR/HER2/TS-IN-2 | Inhibitor | / | Unkown |
| HY-142679 | EGFR-IN-22 | Inhibitor | / | Unkown |
| HY-181701 | EGFR-IN-202 | Inhibitor | / | Unkown |
| HY-163880 | EGFR-IN-119 | Inhibitor | / | Unkown |
| HY-164392 | TAS-121 | Inhibitor | / | Unkown |
| HY-147992 | EGFR/HER2-IN-4 | Inhibitor | / | Unkown |
| HY-144051 | EGFR-IN-34 | Inhibitor | / | Unkown |
| HY-163371 | EGFR WT/T790M-IN-1 | Inhibitor | / | Unkown |
| HY-162323 | EGFR-IN-106 | Inhibitor | / | Unkown |
| HY-147997 | EGFR-IN-68 | Inhibitor | / | Unkown |
| HY-183120 | EGFR T790M/FAK-IN-2 | Inhibitor | / | Unkown |
| HY-103630 | PROTAC Her3 Degrader-2 | Degrader | / | Unkown |
| HY-162483 | EGFR kinase inhibitor 6 | Inhibitor | / | Unkown |
| HY-174415 | ZSH-2117 | Degrader | / | Unkown |
| HY-161731 | DS08701581 | Inhibitor | / | Unkown |
| HY-161067 | EGFR-IN-96 | Inhibitor | / | Unkown |
| HY-P1828 | EGFRvIII peptide (PEPvIII) | / | Unkown | |
| HY-144444 | NSC381467 | Inhibitor | / | Unkown |
| HY-149846 | SIQ17 | Inhibitor | / | Unkown |
| HY-167948 | Dacomitinib metabolite M1/2 | Inhibitor | / | Unkown |
| HY-169309 | EGFR-IN-133 | Inhibitor | / | Unkown |
| HY-178442 | EGFR-IN-179 | Inhibitor | / | Unkown |
| HY-172156 | EGFR-TK-IN-5 | Inhibitor | / | Unkown |
| HY-189142 | EGFR-IN-217 | Inhibitor | / | Unkown |
| HY-149407 | Multi-kinase-IN-4 | Inhibitor | / | Unkown |
| HY-163006 | EGFR/c-Met-IN-1 | Inhibitor | / | Unkown |
| HY-150908 | Brigatinib A | Ligand | / | Unkown |
| HY-169427 | FRF-06-057 | Inhibitor | / | Unkown |
| HY-176556 | EGFR-IN-167 | Inhibitor | / | Unkown |
| HY-149518 | EGFR/BRAFV600E-IN-3 | Inhibitor | / | Unkown |
| HY-172111 | EGFR-IN-144 | Inhibitor | / | Unkown |
| HY-100663 | Gefitinib impurity 2 | 99.56% | Unkown | |
| HY-179485 | EGFR/VEGFR2-IN-10 | Inhibitor | / | Unkown |
| HY-145824 | EGFR-IN-43 | Inhibitor | / | Unkown |
| HY-E70705 | EGFR G719S Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-175220 | 4-TCPA | Inhibitor | / | Unkown |
| HY-147248 | Opadotina | Inhibitor | / | Unkown |
| HY-159512 | EGFR kinase inhibitor 7 | Inhibitor | / | Unkown |
| HY-P11781 | HW12 | Control | / | Unkown |
| HY-168170 | EGFR/VEGFR2-IN-2 | Inhibitor | / | Unkown |
| HY-138298D | Trastuzumab deruxtecan (DAR6) | Inhibitor | / | Unkown |
| HY-158154 | EGFR-IN-110 | Inhibitor | / | Unkown |
| HY-116091 | EGFR-IN-451 | Inhibitor | / | Unkown |
| HY-18298 | PD 173955 analog 1 | Inhibitor | / | Unkown |
| HY-183788 | EGFR-IN-212 | Inhibitor | / | Unkown |
| HY-143874 | HER2-IN-7 | Inhibitor | / | Unkown |
| HY-10261E | (R)-Afatinib | Inhibitor | / | Unkown |
| HY-153557A | HER2-IN-14 | Inhibitor | / | Unkown |
| HY-N16557 | (Rac)-8-Gingerol | Inhibitor | / | Unkown |
| HY-163860 | EGFR-TK-IN-3 | Inhibitor | / | Unkown |
| HY-P10224 | G7-18NATE | / | Unkown | |
| HY-N9684 | Degalactotigonin | Inhibitor | / | Unkown |
| HY-P12120 | ErbB-2-binding peptide-2 | Ligand | / | Unkown |
| HY-178005 | EGFR-IN-174 | Inhibitor | / | Unkown |
| HY-145844 | EGFR-IN-44 | Inhibitor | / | Unkown |
| HY-164399 | SST0116CL1 | Degrader | / | Unkown |
| HY-W174279 | Tyrphostin 8 | Inhibitor | 99.10% | Unkown |
| HY-155227S | ALK/EGFR-IN-1-d5 | Inhibitor | / | Unkown |
| HY-164413 | CLM3 | Inhibitor | / | Unkown |
| HY-100064S | O-Desmethyl gefitinib-d8 | Inhibitor | 99.84% | Unkown |
| HY-163420 | HER2-IN-16 | Inhibitor | / | Unkown |
| HY-113549 | Erbstatin | Inhibitor | / | Unkown |
| HY-158016 | Antiproliferative agent-49 | Inhibitor | / | Unkown |
| HY-155227 | ALK/EGFR-IN-1 | Inhibitor | / | Unkown |
| HY-15772G | Osimertinib (GMP) | Inhibitor | / | Unkown |
| HY-RS04210 | Egfr Mouse Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-170559 | EGFR-IN-141 | Inhibitor | / | Unkown |
| HY-147797 | EGFR/HER2/CDK9-IN-2 | Inhibitor | / | Unkown |
| HY-183123 | EGFR T790M/FAK-IN-1 | Inhibitor | / | Unkown |
| HY-175292 | EGFR WT/T790M-IN-3 | Inhibitor | / | Unkown |
| HY-162602 | EGFR-IN-115 | Inhibitor | / | Unkown |
| HY-162332 | EGFR-PK/JNK-2-IN-1 | Inhibitor | / | Unkown |
| HY-156114 | EGFR/CDK2-IN-2 | Inhibitor | / | Unkown |
| HY-17654 | BIEGi-1 | Inhibitor | / | Unkown |
| HY-RS04471 | Erbb3 Rat Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-144049 | EGFR-IN-32 | Inhibitor | / | Unkown |
| HY-P10995 | TAT-327 | Inhibitor | / | Unkown |
| HY-163417 | HER2-IN-15 | Inhibitor | / | Unkown |
| HY-156991 | NODAGA-NHS | / | Unkown | |
| HY-160613 | EGFR/HER2-IN-11 | Inhibitor | / | Unkown |
| HY-163000 | EGFR-IN-129 | Inhibitor | / | Unkown |
| HY-170543 | Dual Galectin-3/EGFR-IN-1 | Inhibitor | / | Unkown |
| HY-112823S | Almonertinib-d6 | Inhibitor | / | Unkown |
| HY-173492 | EGFR-IN-156 | Inhibitor | / | Unkown |
| HY-179143 | EGFR-IN-185 | Inhibitor | / | Unkown |
| HY-163726 | GLUT1/EGFR-IN-1 | Inhibitor | 99.75% | Unkown |
| HY-183292 | SH-1092 | Inhibitor | / | Unkown |
| HY-P11078 | LARLLT | / | Unkown | |
| HY-147967 | EGFR-IN-63 | Inhibitor | / | Unkown |
| HY-161136 | EGFR/STAT3-IN-1 | Inhibitor | / | Unkown |
| HY-146471 | EGFR-IN-51 | Inhibitor | / | Unkown |
| HY-P10648 | Herceptide | / | Unkown | |
| HY-179049 | EGFR/tubulin-IN-1 | Inhibitor | / | Unkown |
| HY-176788 | EGFR Ligand-Linker Conjugates 1 | Inhibitor | / | Unkown |
| HY-183090 | EGFR/VEGFR2-IN-13 | Inhibitor | / | Unkown |
| HY-179148 | EGFR-IN-184 | Inhibitor | / | Unkown |
| HY-173164 | EGFR/BRAFV600E-IN-4 | Inhibitor | / | Unkown |
| HY-189075 | I-0436650 | Inhibitor | / | Unkown |
| HY-168876 | AZ14240475 | Inhibitor | / | Unkown |
| HY-146474 | EGFR-IN-54 | Inhibitor | / | Unkown |
| HY-173146 | EGFR-IN-153 | Inhibitor | / | Unkown |
| HY-143733 | HER2-IN-5 | Inhibitor | / | Unkown |
| HY-146423 | PROTAC EGFR degrader 6 | Degrader | / | Unkown |
| HY-173218 | anti-NSCLC agent-1 | Inhibitor | / | Unkown |
| HY-168627 | EGFR-IN-135 | Inhibitor | / | Unkown |
| HY-100064S1 | O-Desmethyl gefitinib-d6 | Inhibitor | / | Unkown |
| HY-142519 | EGFR-IN-27 | Inhibitor | / | Unkown |
| HY-120857 | BPIQ-II hydrochloride | Inhibitor | / | Unkown |
| HY-179039 | EGFR-IN-183 | Inhibitor | / | Unkown |
| HY-169982 | EGFR-IN-136 | Inhibitor | / | Unkown |
| HY-180242 | EGFR/CDK2-IN-5 | Inhibitor | / | Unkown |
| HY-143246 | EGFR kinase inhibitor 1 | Inhibitor | / | Unkown |
| HY-171443 | Lyso-Monosialoganglioside GM3 | Inhibitor | / | Unkown |
| HY-W714853 | (+)-Theta-cypermethrin | Ligand | / | Unkown |
| HY-151882 | EGFR-IN-73 | Inhibitor | / | Unkown |
| HY-158176 | EGFR T790M/L858R-IN-5 | Inhibitor | / | Unkown |
| HY-144056 | EGFR-IN-39 | Inhibitor | / | Unkown |
| HY-151154 | EGFR/HER2/DHFR-IN-1 | Inhibitor | / | Unkown |
| HY-178955 | EGFR-IN-182 | Inhibitor | / | Unkown |
| HY-153856A | TAS2940 fumarate | Inhibitor | / | Unkown |
| HY-142681 | EGFR-IN-28 | Inhibitor | / | Unkown |
| HY-157432 | EGFR-IN-97 | Inhibitor | / | Unkown |
| HY-127067 | Yuanhuadin | Inhibitor | / | Unkown |
| HY-168514 | SOS1/EGFR-IN-2 | Inhibitor | / | Unkown |
| HY-178824 | EGFR-IN-180 | Inhibitor | / | Unkown |
| HY-177989 | ER121 | Inhibitor | 98.52% | Unkown |
| HY-160682 | EGFR/HER2-IN-12 | Inhibitor | / | Unkown |
| HY-161319 | EGFR-IN-104 | Inhibitor | / | Unkown |
| HY-176279 | Hsp90-IN-42 | Inhibitor | / | Unkown |
| HY-184497 | PROTAC EGFR degrader 18 | Degrader | / | Unkown |
| HY-168427 | Avitinib maleate dihydrate | Inhibitor | / | Unkown |
| HY-181099 | EGFR WT/T790M-IN-4 | Inhibitor | / | Unkown |
| HY-184274 | EGFR/c-SRC-IN-1 | Inhibitor | / | Unkown |
| HY-159101 | EP26 | Inhibitor | / | Unkown |
| HY-147802 | EGFR-IN-59 | Inhibitor | / | Unkown |
| HY-146782 | EGFR-IN-49 | Inhibitor | / | Unkown |
| HY-E70701 | EGFR d747-749/A750P Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-179140 | EGFR/VEGFR2-IN-8 | Inhibitor | / | Unkown |
| HY-141486A | PROTAC PARP/EGFR ligand 1 | / | Unkown | |
| HY-162881 | DS06652923 | Inhibitor | / | Unkown |
| HY-183253 | DL149 | Ligand | / | Unkown |
| HY-114535 | Jaceidin | Inhibitor | / | Unkown |
| HY-P10686 | CH401 peptide | / | Unkown | |
| HY-151162 | HER2-IN-12 | Inhibitor | / | Unkown |
| HY-177270 | CHNQD-01281 | Modulator | / | Unkown |
| HY-13272S3 | Dacomitinib-d10 | Inhibitor | / | Unkown |
| HY-176938 | AfaPhos1 | Inhibitor | / | Unkown |
| HY-160828 | O-Desmethyl dacomitinib | Inhibitor | / | Unkown |
| HY-149632 | EGFR/HER2/DHFR-IN-2 | Inhibitor | / | Unkown |
| HY-156457 | EGFR-IN-90 | Inhibitor | / | Unkown |
| HY-RS04469 | ERBB3 Human Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-P11590 | WGYRGFYC | Ligand | / | Unkown |
| HY-170661 | EGFR-IN-142 | Inhibitor | / | Unkown |
| HY-180965 | Pro-PEG3-BA | Degrader | / | Unkown |
| HY-175257 | Theophylline-platinum(IV) prodrug-1 | Inhibitor | / | Unkown |
| HY-184116 | A2AR/EGFR-IN-1 | Inhibitor | / | Unkown |
| HY-172471 | DSPE-PEG5000-GE11 | / | Unkown | |
| HY-183373 | EGFR/PARP-1-IN-1 | Inhibitor | / | Unkown |
| HY-161269 | EGFR-IN-101 | Inhibitor | / | Unkown |
| HY-175635 | EGFR/VEGFR2-IN-6 | Inhibitor | / | Unkown |
| HY-175531 | EGFR-IN-169 | Inhibitor | / | Unkown |
| HY-144441 | NSC81111 | Inhibitor | / | Unkown |
| HY-144794 | EGFR-IN-46 | Inhibitor | / | Unkown |
| HY-158969 | EGFR-IN-113 | Inhibitor | / | Unkown |
| HY-101960 | (Z)-Tyrphostin A51 | Inhibitor | / | Unkown |
| HY-147996 | EGFR-IN-67 | Inhibitor | / | Unkown |
| HY-161045 | T-1-DOCA | Inhibitor | / | Unkown |
| HY-RS04470 | Erbb3 Mouse Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-181251 | EGFR-IN-195 | Inhibitor | / | Unkown |
| HY-175608 | EGFR-IN-171 | Inhibitor | / | Unkown |
| HY-142283CS | N-Methyl-dosimertinib-d5 | / | Unkown | |
| HY-10368 | EGFR/VEGFR2-IN-4 | Inhibitor | / | Unkown |
| HY-182264 | Masoprocol tetrapivalate | Inhibitor | / | Unkown |
| HY-175864 | EGFR-IN-173 | Inhibitor | / | Unkown |
| HY-E70696 | EGFR C797S/L858R Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-149344 | Anticancer agent 133 | Inhibitor | / | Unkown |
| HY-162148 | HNPMI | Inhibitor | 99.57% | Unkown |
| HY-172470A | DSPE-PEG3400-GE11 | / | Unkown | |
| HY-172961 | EGFR-IN-162 | Inhibitor | / | Unkown |
| HY-135216 | Antiproliferative agent-54 | Inhibitor | / | Unkown |
| HY-161146 | EGFR-IN-100 | Inhibitor | / | Unkown |
| HY-P990049A | Becotatug (powder) | Inhibitor | / | Unkown |
| HY-P11613 | DOTA-WC8 | Ligand | / | Unkown |
| HY-161866 | EGFR-IN-118 | Inhibitor | / | Unkown |
| HY-162623 | EGFR/HER2-IN-15 | Inhibitor | / | Unkown |
| HY-161145 | EGFR/microtubule-IN-1 | Inhibitor | / | Unkown |
| HY-155079A | (R)-DZD1516 | Control | 98.80% | Unkown |
| HY-116059 | EGFR-IN-199 | Inhibitor | / | Unkown |
| HY-142678 | EGFR-IN-21 | Inhibitor | / | Unkown |
| HY-181491 | Tubulin-IN-64 | Inhibitor | / | Unkown |
| HY-142283BS | N-Desmethyl dosimertinib-d5 | / | Unkown | |
| HY-161031 | EGFR-IN-93 | Inhibitor | / | Unkown |
| HY-177379 | EGFR ligand-14 | / | Unkown | |
| HY-161891 | EGFR/Akt-IN-1 | Inhibitor | / | Unkown |
| HY-155969 | EGFR-IN-83 | Inhibitor | / | Unkown |
| HY-168112 | EGFR-IN-127 | Inhibitor | / | Unkown |
| HY-161602 | EGFR/HER2-IN-13 | Inhibitor | / | Unkown |
| HY-121828 | TX-1123 | Inhibitor | / | Unkown |
| HY-123891 | NS-062 | Inhibitor | / | Unkown |
| HY-173501 | EGFR-IN-157 | Inhibitor | / | Unkown |
| HY-116277 | Z118332870 | Inhibitor | / | Unkown |
| HY-175173 | EGFR-IN-166 | Inhibitor | / | Unkown |
| HY-156470 | Multi-kinase-IN-6 | Inhibitor | / | Unkown |
| HY-171252 | EGFR-IN-145 | Inhibitor | / | Unkown |
| HY-179031 | EGFR/VEGFR2-IN-7 | Inhibitor | / | Unkown |
| HY-100636 | Gefitinib N-oxide | Inhibitor | / | Unkown |
| HY-178283 | EGFR-IN-177 | Inhibitor | / | Unkown |
| HY-115952 | EGFR/HER2-IN-3 | Inhibitor | / | Unkown |
| HY-162482 | EGFR kinase inhibitor 5 | Inhibitor | / | Unkown |
| HY-157912 | EGFR-IN-102 | Inhibitor | / | Unkown |
| HY-162360 | EGFR-IN-109 | Inhibitor | / | Unkown |
| HY-129288 | GW837016X | Inhibitor | / | Unkown |
| HY-145823 | EGFR-IN-42 | Inhibitor | / | Unkown |
| HY-RS04473 | Erbb4 Mouse Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-E70699 | EGFR d746-750/T790M/C797S Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-150905 | EGFR ligand-2 | Inhibitor | / | Unkown |
| HY-183311 | EGFR-IN-211 | Inhibitor | / | Unkown |
| HY-169408 | EGFR-IN-137 | Inhibitor | / | Unkown |
| HY-173619 | EGFR-IN-160 | Inhibitor | / | Unkown |
| HY-160564 | ZNL-0056 | Inhibitor | / | Unkown |
| HY-181115 | EGFR-IN-193 | Inhibitor | / | Unkown |
| HY-168173 | EGFR-IN-130 | Inhibitor | / | Unkown |
| HY-180949 | EGFR-IN-189 | Inhibitor | / | Unkown |
| HY-146238 | EGFR/HER2/TS-IN-1 | Inhibitor | / | Unkown |
| HY-168492 | TrxR/EGFR-IN-1 | Inhibitor | / | Unkown |
| HY-P10793 | Cyclic(YCDGFYACYMDV) | Inhibitor | / | Unkown |
| HY-144050 | EGFR-IN-33 | Inhibitor | / | Unkown |
| HY-168469 | EGFR-IN-148 | Inhibitor | / | Unkown |
| HY-13050A | Sapitinib fumarate | Inhibitor | / | Unkown |
| HY-179522 | EGFR-IN-186 | Inhibitor | / | Unkown |
| HY-18213 | EGFR-IN-9 | Inhibitor | 98.69% | Unkown |
| HY-174841 | EGFR/HER2-IN-19 | Inhibitor | / | Unkown |
| HY-162300 | EGFR kinase inhibitor 4 | Inhibitor | / | Unkown |
| HY-168433 | LSD1/EGFR-IN-1 | Inhibitor | / | Unkown |
| HY-181766 | EGFR/VEGFR2-IN-11 | Inhibitor | / | Unkown |
| HY-172469 | DSPE-PEG1000-GE11 | / | Unkown | |
| HY-177009 | Tucatinib analog B | Ligand | / | Unkown |
| HY-50896S1 | Erlotinib-13C6 | Inhibitor | / | Unkown |
| HY-181923 | IMP-Zn | / | Unkown | |
| HY-115933 | EGFR/BRAF-IN-1 | Inhibitor | / | Unkown |
| HY-179098 | Multi-target kinase-IN-8 | Inhibitor | / | Unkown |
| HY-184720 | VEGFR-2-IN-89 | Inhibitor | / | Unkown |
| HY-155074 | EGFR-IN-79 | Inhibitor | / | Unkown |
| HY-109061A | Lazertinib mesylate hydrate | Inhibitor | / | Unkown |
| HY-169346 | Pred17 | Inhibitor | / | Unkown |
| HY-175805 | EGFR/HDAC-IN-2 | Inhibitor | / | Unkown |
| HY-176938A | iAfaPhos1 | / | Unkown | |
| HY-W777297 | Lapatinib-13C2,15N Ditosylate | / | Unkown | |
| HY-133453 | PROTAC EGFR degrader 1 | Degrader | / | Unkown |
| HY-144055 | EGFR-IN-38 | Inhibitor | / | Unkown |
| HY-178009 | EGFR-IN-175 | Inhibitor | / | Unkown |
| HY-178142 | Multi-kinase-IN-7 | Inhibitor | / | Unkown |
| HY-RS04467 | Erbb2 Mouse Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-161968 | EGFR/PI3Kα-IN-1 | Inhibitor | / | Unkown |
| HY-164988 | TX2-120-1 | Degrader | / | Unkown |
| HY-10261S1 | Afatinib-d4 | Inhibitor | / | Unkown |
| HY-178353 | EGFR/Cytokine-IN-1 | Inhibitor | / | Unkown |
| HY-146210 | EGFR-IN-50 | Inhibitor | / | Unkown |
| HY-169216 | Multi-target kinase inhibitor 3 | Inhibitor | / | Unkown |
| HY-118175 | RG 14921 | Inhibitor | / | Unkown |
| HY-161030 | EGFR-IN-92 | Inhibitor | / | Unkown |
| HY-185780 | Trastuzumab-DM21 | Inhibitor | / | Unkown |
| HY-P11890 | GPVGPS | Modulator | / | Unkown |
| HY-161785 | EGFR-IN-117 | Inhibitor | / | Unkown |
| HY-P11484 | Myosin Regulatory Light Chain MRCL3 (11-24) | / | Unkown | |
| HY-187191 | Autophagy-IN/Ferroptosis inducer-modulator-1 | Inhibitor | / | Unkown |
| HY-161632 | PROTAC EGFR degrader 10 | Degrader | / | Unkown |
| HY-146132 | EGFR-IN-55 | Inhibitor | / | Unkown |
| HY-143323 | HER2-IN-9 | Inhibitor | / | Unkown |
| HY-163402 | EGFR-IN-108 chloride | Inhibitor | / | Unkown |
| HY-146325 | HSP90-IN-11 | Degrader | / | Unkown |
| HY-146422 | PROTAC EGFR degrader 5 | Degrader | / | Unkown |
| HY-172110 | Apoptosis inducer 35 | Inhibitor | / | Unkown |
| HY-149517 | EGFR/BRAFV600E-IN-2 | Inhibitor | / | Unkown |
| HY-153605 | EGFR-IN-77 | Inhibitor | / | Unkown |
| HY-151156 | EGFR/HER2-IN-6 | Inhibitor | / | Unkown |
| HY-184301 | EGFR/HER2-IN-20 | Inhibitor | / | Unkown |
| HY-B0793GL | AZ-5104 (GMP Like) | Inhibitor | / | Unkown |
| HY-185460 | Pertuzumab-LD3 | Inhibitor | / | Unkown |
| HY-172966 | EG31 | Inhibitor | / | Unkown |
| HY-149401 | EGFR-IN-82 | Inhibitor | / | Unkown |
| HY-143445 | EGFR-IN-48 | Inhibitor | / | Unkown |
| HY-175316 | EGFR-IN-168 | Inhibitor | / | Unkown |
| HY-187517 | Anticancer agent 357 | Inhibitor | / | Unkown |
| HY-P1085 | Epidermal Growth Factor Receptor Peptide (985-996) | Chemical | / | Unkown |
| HY-170497 | EGFR-IN-140 | Inhibitor | / | Unkown |
| HY-170665 | EGFR T790M/L858R-IN-9 | Inhibitor | / | Unkown |
| HY-179599 | Dyrk1A-IN-15 | Inhibitor | / | Unkown |
| HY-151573 | EGFR/CDK2-IN-1 | Inhibitor | / | Unkown |
| HY-163723 | EGFR-IN-116 | Inhibitor | / | Unkown |
| HY-175011 | EGFR-IN-165 | Inhibitor | / | Unkown |
| HY-163377 | AZ5385 | Inhibitor | / | Unkown |
| HY-159519 | EGFR/HER2-IN-16 | Inhibitor | / | Unkown |
| HY-P11757 | Cyclo[K(N3)larllt] | Ligand | / | Unkown |
| HY-151158 | EGFR/HER2-IN-7 | Inhibitor | / | Unkown |
| HY-163419 | HER2-IN-18 | Inhibitor | / | Unkown |
| HY-153557 | HER2-IN-13 | Inhibitor | / | Unkown |
| HY-E70706 | EGFR L718Q Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-146472 | EGFR-IN-52 | Inhibitor | / | Unkown |
| HY-175009 | MRC-G-001 | Inhibitor | / | Unkown |
| HY-146154 | EGFR-IN-58 | Inhibitor | / | Unkown |
| HY-50898S5 | Lapatinib-13C,d7 | Inhibitor | / | Unkown |
| HY-137028 | 2′-Thioadenosine | Inhibitor | / | Unkown |
| HY-161603 | EGFR/HER2-IN-14 | Inhibitor | / | Unkown |
| HY-100636A | Gefitinib N-oxide hydrochloride | Inhibitor | / | Unkown |
| HY-144676 | pan-HER-IN-1 | Inhibitor | / | Unkown |
| HY-18957A | rel-Lifirafenib | Control | / | Unkown |
| HY-P5742A | ELAAWCRWGFLLALLPPGIAG TFA | / | Unkown | |
| HY-143901 | EGFR-IN-40 | Inhibitor | / | Unkown |
| HY-156116 | EGFR/CDK2-IN-4 | Inhibitor | / | Unkown |
| HY-178119 | HER4/HER2-IN-1 | Inhibitor | / | Unkown |
| HY-120412 | SKLB188 | Inhibitor | / | Unkown |
| HY-173520 | EGFR/HDAC-IN-1 | Inhibitor | / | Unkown |
| HY-170932 | EGFR/COX-2-IN-1 | Inhibitor | / | Unkown |
| HY-175820 | AGW-11 | Inhibitor | / | Unkown |
| HY-172179 | EGFR/VEGFR2-IN-5 | Inhibitor | / | Unkown |
| HY-RS04474 | Erbb4 Rat Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-174414 | EGFR/HER2-IN-18 | Inhibitor | / | Unkown |
| HY-162964 | EGFR-IN-126 | Inhibitor | / | Unkown |
| HY-175162 | EGFR ligand-20 | Ligand | / | Unkown |
| HY-103629 | PROTAC Her3 Degrader-1 | Inhibitor | / | Unkown |
| HY-114253 | ODS-2004436 | / | Unkown | |
| HY-P10569 | Biotin HER-2 substrate peptide | / | Unkown | |
| HY-138298B | Trastuzumab deruxtecan (DAR2) | Inhibitor | / | Unkown |
| HY-183754 | EGFR-IN-213 | Inhibitor | / | Unkown |
| HY-110328 | PKI-166 hydrochloride | Inhibitor | / | Unkown |
| HY-150781 | EGFR-IN-71 | Inhibitor | / | Unkown |
| HY-104080 | HG-5-88-01 | Inhibitor | / | Unkown |
| HY-173314 | EGFR-IN-155 | Inhibitor | / | Unkown |
| HY-162062 | EGFR WT/T790M/L858R-IN-1 | Inhibitor | / | Unkown |
| HY-138627B | AST5902 mesylate | Inhibitor | / | Unkown |
| HY-117852 | CGP-59326 | Inhibitor | / | Unkown |
| HY-P11760 | HER2-targeted peptide H10 | Ligand | / | Unkown |
| HY-180154 | EGFR/BRAFV600E-IN-6 | Inhibitor | / | Unkown |
| HY-107450 | PROTAC Her3-binding moiety 2 | Inhibitor | / | Unkown |
| HY-181777 | Mal-Pip-ValCit-PAB-AZ7550 | Inhibitor | / | Unkown |
| HY-181093 | EGFR-IN-191 | Inhibitor | / | Unkown |
| HY-164503 | Neptinib | Inhibitor | / | Unkown |
| HY-12008S1 | Erlotinib-13C6 hydrochloride | Inhibitor | / | Unkown |
| HY-147826 | EGFR-IN-60 | Inhibitor | / | Unkown |
| HY-181479 | EGFR-IN-196 | Inhibitor | / | Unkown |
| HY-178939 | EGFR-IN-181 | Inhibitor | / | Unkown |
| HY-144445 | NSC114126 | Inhibitor | / | Unkown |
| HY-161320 | EGFR-IN-105 | Inhibitor | / | Unkown |
| HY-157324 | EGFR-IN-94 | Inhibitor | / | Unkown |
| HY-156033 | EGFR-IN-88 | Inhibitor | / | Unkown |
| HY-169568 | EGFR-IN-147 | Inhibitor | / | Unkown |
| HY-182031 | JS04 | Inhibitor | / | Unkown |
| HY-168064 | EGFR-IN-124 | Inhibitor | / | Unkown |
| HY-182742 | EGFR-IN-208 | Inhibitor | / | Unkown |
| HY-N6678S | (Rac)-Zearalanone-d6 | Degrader | / | Unkown |
| HY-E70695 | EGFR C797S Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-172780 | EGFR-IN-161 | Inhibitor | / | Unkown |
| HY-168073 | EGFR/VEGFR2-IN-1 | Inhibitor | / | Unkown |
| HY-146473 | EGFR-IN-53 | Inhibitor | / | Unkown |
| HY-116138 | RG-14467 | Inhibitor | / | Unkown |
| HY-164490 | LS-106 | Inhibitor | / | Unkown |
| HY-144044 | EGFR-IN-30 | Inhibitor | / | Unkown |
| HY-137786 | EGFR-IN-16 | Inhibitor | / | Unkown |
| HY-147994 | EGFR/HER2-IN-5 | Inhibitor | / | Unkown |
| HY-180823 | Topoisomerase II/EGFR-IN-2 | Inhibitor | / | Unkown |
| HY-E70700 | EGFR d746-750/T790M/C797S/L858R Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-157526 | EGFR-TK-IN-1 | Inhibitor | / | Unkown |
| HY-P0221A | PACAP (1-38), human, ovine, rat TFA | Inducer | / | Unkown |
| HY-156115 | EGFR/CDK2-IN-3 | Inhibitor | / | Unkown |
| HY-174826 | EGFR-IN-164 | Inhibitor | / | Unkown |
| HY-178440 | EGFR/COX-2-IN-2 | Inhibitor | / | Unkown |
| HY-112334 | EGFR-IN-198 | Inhibitor | / | Unkown |
| HY-177380 | EGFR ligand-14-PEG3-Boc | / | Unkown | |
| HY-144053 | EGFR-IN-36 | Inhibitor | / | Unkown |
| HY-172160 | HER2-IN-21 | Inhibitor | / | Unkown |
| HY-155200 | EGFR-IN-84 | Inhibitor | / | Unkown |
| HY-E70702 | EGFR d747-752/P753S Recombinant Human Active Protein Kinase | / | Unkown | |
| HY-146138 | EGFR-IN-57 | Inhibitor | / | Unkown |
| HY-170438 | EGFR-IN-139 | / | Unkown | |
| HY-142517 | EGFR-IN-25 | Inhibitor | / | Unkown |
| HY-163632 | EGFR-IN-112 | Inhibitor | / | Unkown |
| HY-146136 | EGFR-IN-56 | Inhibitor | / | Unkown |
| HY-178313 | EGFR ligand-18 | Degrader | / | Unkown |
| HY-180196 | EGFR-IN-187 | Inhibitor | / | Unkown |
| HY-W409652 | CLK1/4-IN-2 | Inhibitor | / | Unkown |
| HY-143729 | EGFR-IN-29 | Inhibitor | / | Unkown |
| HY-50898S1 | Lapatinib-d7 dihydrochloride | Inhibitor | / | Unkown |
| HY-10188 | SKS-927 | Inhibitor | / | Unkown |
| HY-187692 | IRAK4-IN-35 | Inhibitor | / | Unkown |
| HY-149695 | EGFR-IN-91 | Inhibitor | / | Unkown |
| HY-162788 | EGFR-IN-121 | Inhibitor | / | Unkown |
| HY-P10994 | Eps8 peptide 327 | Inhibitor | / | Unkown |
| HY-181166 | EGFR-IN-194 | Inhibitor | / | Unkown |
| HY-158175 | EGFR T790M/L858R-IN-4 | Inhibitor | / | Unkown |
| HY-169428 | EGFR-IN-138 | / | Unkown | |
| HY-147825 | EGFR/BRAFV600E-IN-1 | Inhibitor | / | Unkown |
| HY-168559 | EGFR-IN-131 | Inhibitor | / | Unkown |
| HY-182817 | Len-604 | Inhibitor | / | Unkown |
| HY-183402 | FLLL12 | Inhibitor | / | Unkown |
| HY-169566 | EGFR-IN-146 | Inhibitor | / | Unkown |
| HY-N14635 | Paeciloquinone A | Inhibitor | / | Unkown |
| HY-W740378 | 1,2,3,4-Tetrahydro Staurosporin | Inhibitor | / | Unkown |
| HY-180325 | DDC4002 | Inhibitor | / | Unkown |
| HY-169755 | Tyrphostin 63 | Inhibitor | / | Unkown |
| HY-137081 | AKOS024836912 | Inhibitor | / | Unkown |
| HY-158829A | SSOe26 sodium scrambled negative control | / | Unkown | |
| HY-N14637 | Paeciloquinone C | Inhibitor | / | Unkown |
| HY-183397 | Avitinib dihydrochloride | Inhibitor | / | Unkown |
| HY-10263 | BMS-554417 | Activator | / | Unkown |
| HY-16069S | Tucatinib-d6 | Inhibitor | / | Unkown |
| HY-118032 | Bozepinib | Inhibitor | / | Unkown |
| HY-183377 | DMBT | Inhibitor | / | Unkown |
| HY-158828A | SSO111 sodium scrambled negative control | / | Unkown | |
| HY-32718S | Pelitinib-d6 | / | Unkown | |
| HY-114667 | Lavendustin C6 | Inhibitor | / | Unkown |
| HY-135727 | PF-6422899 | Inhibitor | / | Unkown |
| HY-50896S2 | Erlotinib-d4 | Inhibitor | / | Unkown |
| HY-180498 | NSC 57148 | Inhibitor | / | Unkown |
| HY-116068 | DW532 | Inhibitor | / | Unkown |
| HY-156487 | CNBDA | Inhibitor | / | Unkown |
| HY-169948 | BML-265 | Inhibitor | / | Unkown |
| HY-183456 | Tyrphostin AG17 | Inhibitor | / | Unkown |
| HY-168305 | EGFR ligand-11 | / | Unkown | |
| HY-111072 | ADS103317 | / | Unkown | |
| HY-160068 | 2-2(t) aptamer sodium | Chemical | 99.28% | Unkown |
| HY-158829 | SSOe26 sodium | / | Unkown | |
| HY-184315 | LDC8201 | Inhibitor | / | Unkown |
| HY-N14636 | Paeciloquinone B | Inhibitor | / | Unkown |
| HY-117523 | (Z)-RG-13022 | Inhibitor | / | Unkown |
| HY-19909A | NRC-2694-A | Inhibitor | / | Unkown |
| HY-N20729 | Eucommin A | Modulator | / | Unkown |
| HY-N14639 | Paeciloquinone E | Inhibitor | / | Unkown |
| HY-15495B | (3S)-Tanzisertib hydrochloride | Inhibitor | / | Unkown |
| HY-110045 | ZM-306416 hydrochloride | Inhibitor | / | Unkown |
| HY-N14638 | Paeciloquinone D | Inhibitor | / | Unkown |
| HY-153887 | HyT36(-Cl) | Control | / | Unkown |
| HY-50896S3 | Erlotinib-d8 | Inhibitor | / | Unkown |
| HY-32721S | Neratinib-d6 | Inhibitor | / | Unkown |
| HY-183400 | BIM-46174 | Inhibitor | / | Unkown |
| HY-111250 | SYR127063 | Inhibitor | / | Unkown |
| HY-163396 | EGFR-IN-107 | Inhibitor | / | Unkown |
| HY-159047 | EGFR ligand-10 | Degrader | / | Unkown |
| HY-178740 | GI261520A | Inhibitor | / | Unkown |
| HY-164527 | Si306 | Inhibitor | / | Unkown |
| HY-15769A | WHI-P180 hydrochloride | Inhibitor | / | Unkown |
| HY-103443A | HKI-357 dimaleate | Inhibitor | / | Unkown |
| HY-180480 | NSC 104999 | Ligand | / | Unkown |
| HY-135725 | D-69491 hydrochloride | Inhibitor | / | Unkown |
| HY-10325R | CL-387785 (Standard) | Inhibitor | / | Unkown |
| HY-117252 | HS-72 | / | Unkown | |
| HY-50898CS | Lapatinib-d4 tosylate | Inhibitor | / | Unkown |
| HY-111300 | G3130 | Degrader | / | Unkown |
| HY-158828 | SSO111 sodium | / | Unkown | |
| HY-50898S4 | Lapatinib-d7 | Inhibitor | / | Unkown |
| HY-100742R | GNE-140 racemate (Standard) | Inhibitor | / | Unkown |
| HY-169570 | EGFR-IN-149 | Inhibitor | / | Unkown |
| HY-146262 | LDC0496 | Inhibitor | / | Unkown |
| 製品番号 | 製品名 |
製品効果
|
純度 |
Rare Diseases
|
|---|---|---|---|---|
| HY-P9907A | Trastuzumab (anti-HER2) | Inhibitor | 99.838% | Unkown |
| HY-P9S0008 | Cetuximab (PBS) | Inhibitor | 99.33% | Unkown |
| HY-P99854 | Disitamab | Inhibitor | 98.73% | Unkown |
| HY-P9912A | Pertuzumab (anti-HER2) | Inhibitor | 99.10% | Unkown |
| HY-P990947 | Tilatamig | Inhibitor | 99.99% | Unkown |
| HY-P990957 | Ficerafusp alfa | 99.71% | Unkown | |
| HY-P99866 | Duligotuzumab | Inhibitor | 99.17% | Unkown |
| HY-P99684 | Laprituximab | Inhibitor | 99.74% | Unkown |
| HY-P990238 | Anti-Human/Rat HER2 (neu) Antibody (7.16.4) | Inhibitor | 95.00% | Unkown |
| HY-P991748 | Anti-Human/Mouse Amphiregulin Antibody (AR37) | Inhibitor | 99.544% | Unkown |
| HY-P9977A | Amivantamab (FUT8-KO) | Inhibitor | 98% | Unkown |
| HY-P990755 | Pamvatamig | 95.298% | Unkown | |
| HY-P99892 | Serclutamab | 99.97% | Unkown | |
| HY-P99948 | Etevritamab | 97.00% | Unkown | |
| HY-P99324 | Tomuzotuximab | Inhibitor | ≥99.0% | Unkown |
| HY-P99715 | Losatuxizumab | Inhibitor | 99.44% | Unkown |
| HY-P99406A | Petosemtamab (FUT8-KO) | Degrader | 99% | Unkown |
| HY-P99618 | Fidasimtamab | Inhibitor | 95.00% | Unkown |
| HY-P991662 | AMG-595 Antibody | 96.94% | Unkown | |
| HY-P99558 | Timigutuzumab | Inhibitor | 97.53% | Unkown |
| HY-P990978 | Caxmotabart | 96.56% | Unkown | |
| HY-P990909 | Calotatug | 98% | Unkown | |
| HY-P99888 | Pimurutamab | 99.42% | Unkown | |
| HY-P990962 | Vislarafusp alfa | 98.98% | Unkown | |
| HY-P991159 | Ruzaltatug | Inhibitor | 95.69% | Unkown |
| HY-P991780 | Anti-Mouse HER2 (domain I) Antibody (H2Mab-304) | Inhibitor | 97.589% | Unkown |
| HY-P990695 | Lunaxafusp (His Tag) | Inhibitor | / | Unkown |
| HY-P992137 | Turigrobart | Inhibitor | 99.9% | Unkown |
| HY-P991505 | Anti-HER3 Antibody (Ab562) | Antagonist | 99.63% | Unkown |
| HY-P991779 | Anti-Mouse/Human/Canine HER2 (domain III) Antibody (H2Mab-19) | Inhibitor | 99.05% | Unkown |
| HY-P992107 | Dulpatatug | Inhibitor | 99.09% | Unkown |
| HY-P990972 | Azerutamig | / | Unkown | |
| HY-P991966 | Anti-Human/Mouse EGFR Antibody (7A7) | 99.45% | Unkown | |
| HY-P992140 | Varzutamig | Inhibitor | / | Unkown |
| HY-P990408 | Anti-ERBB1/EGFR/HER1 Antibody | Inhibitor | / | Unkown |
| HY-P991236 | MHES0488A | Inhibitor | / | Unkown |
| HY-P990755A | Pamvatamig (FUT8-KO) | Inhibitor | / | Unkown |
| HY-P991986 | Anti-Epiregulin Antibody | Inhibitor | / | Unkown |
| HY-P991980 | H2Mab-139 | Inhibitor | / | Unkown |
| HY-P991241 | Anti-ERBB3/HER3 (29Z6) | Inhibitor | / | Unkown |
| HY-P992401 | M802 | Inhibitor | / | Unkown |
| HY-P991970 | REGN3124 | Inhibitor | / | Unkown |
| HY-P991967 | AVID100 Antibody | Inhibitor | / | Unkown |
| HY-P9968A | Nimotuzumab (powder) | Inhibitor | / | Unkown |
| HY-P991245 | Anti-ERBB3/HER3 (SGP1) | Inhibitor | / | Unkown |
| HY-P991985 | Anti-Her4 Antibody | Inhibitor | / | Unkown |
| HY-P991784 | Anti-Mouse/Human EGFR (domain III) Antibody (EMab-88) | Inhibitor | / | Unkown |
| HY-P990248 | Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1) | Inhibitor | 98.53% | Unkown |
| HY-P991573 | Anti-EGFR Antibody (D2C7) | Inhibitor | / | Unkown |
| HY-P991968 | HTI-1511 Antibody | Inhibitor | / | Unkown |
| HY-P991243 | MP-RM-1 | Inhibitor | 96.29% | Unkown |
| HY-P991092A | IBI-334 (FUT8-KO) | Inhibitor | / | Unkown |
| HY-P991239 | NM-02 | Inhibitor | / | Unkown |
| HY-P99295A | Imgatuzumab (FUT8-KO) | Inhibitor | / | Unkown |
| HY-P991977 | BSI-001 | Inhibitor | / | Unkown |
| HY-P991234 | COVA208 | Degrader | / | Unkown |
| HY-P991969 | LR004 | Inhibitor | / | Unkown |
| HY-P992171 | ADCT-701 Antibody | / | Unkown | |
| HY-P991783 | Anti-Mouse EGFR (domain I) Antibody (EMab-300) | Inhibitor | / | Unkown |
| HY-P991979 | Erbicin | Inhibitor | / | Unkown |